Advances in Drug Delivery Systems Utilizing Glycyrrhizic Acid and Its Aglycone Glycyrrhetinic Acid in Cancer Therapy Authors: Shanshan Liu, Dongyan Guo, Huan Tian, Jiangxue Cheng, Yajun Shi, Xiaofei Zhang, Junbo Zou, Bingtao Zhai Published: 2026 ABSTRACT AbstractGlycyrrhizic acid (GL) and glycyrrhetinic acid (GA) exhibit antitumor activity, favorable biocompatibility, receptor-targeting capabilities, and amphiphilicity. These properties make them promising multifunctional components for developing antitumor drug delivery systems. Unlike previous reviews that focus on individual applications, this review systematically categorizes GL/GA according to their three functional roles. First, as therapeutic agents, GL/GA can be incorporated into passively targeted, actively targeted, and stimuli-responsive nanocarriers. They can be combined with chemotherapeutic drugs, such as cisplatin and paclitaxel, to enhance therapeutic efficacy and reduce systemic toxicity. Second, as targeting ligands, GL/GA can be conjugated to the surfaces of nanocarriers to enable receptor-mediated tumor delivery. Finally, as self-assembling materials, GL/GA can co-assemble with other drugs to form carrier-free nanostructures. Alternatively, they can serve as building blocks for polymeric carriers. These strategies enable drug–carrier integration, simplify formulation processes, and enhance synergistic antitumor effects. Furthermore, this review analyzes the key challenges in the clinical translation of these formulations. These challenges include the complexity of large-scale production, insufficient in vivo stability, a lack of long-term safety data, and inconsistencies in quality evaluation systems. Future translational prospects are also outlined to guide the rational design and clinical development of natural product-based nanomedicines. Introduction Cancer remains one of the leading causes of death globally, with its high incidence and mortality rates constituting a significant global health burden.1 According to the latest systematic analysis from the Global Burden of Disease (GBD) 2023 study, excluding non-melanoma skin cancer, approximately 18.5 million new cancer cases were diagnosed globally in 2023, resulting in about 10.4 million deaths. The study further predicts that by 2050, global cancer incidence and mortality will rise to 30.5 million (UI: 22.9–38.9 million) and 18.6 million (UI: 15.6–21.5 million), respectively.2 This signifies that cancer is the second leading cause of death globally after cardiovascular disease, highlighting its high mortality rate. Traditional treatments, such as chemotherapy, radiotherapy, immunotherapy, and small-molecule targeted therapies, can partially suppress tumor progression.3 However, significant limitations persist: chemotherapy drugs commonly suffer from poor water solubility, low bioavailability, and limited tumor targeting, leading to severe systemic toxicity (eg, bone marrow suppression, liver/kidney damage).4 Immunotherapy applications are constrained by immune-related adverse events (irAEs) and resistance arising from immunosuppressive tumor microenvironments (eg, hypoxia).5 Small-molecule targeted drugs face resistance due to target mutations or bypass pathway activation, coupled with limited adaptability to tumor heterogeneity.6 Simultaneously, multiple treatment modalities may induce multidrug resistance through mechanisms such as P-glycoprotein-mediated drug efflux, mutations in drug targets, or remodeling of the tumor microenvironment.7–9 These mechanisms further reduce treatment efficacy and limit the safety and applicability of current treatments. Against this backdrop, natural product-derived drugs offer promising approaches to overcoming existing therapeutic limitations, owing to their multitarget effects, low toxicity, and ability to modulate the tumor microenvironment. Natural product-derived compounds exhibit diverse biological activities. They can directly inhibit tumor cell proliferation and induce apoptosis. They can also exert antitumor effects through immune regulation and modulation of the tumor microenvironment. They typically demonstrate favorable biocompatibility and safety profiles. Licorice, a traditional Chinese medicinal and edible plant, has a history of medicinal use dating back to the Divine Farmer’s Classic of Materia Medica. Modern pharmacological research confirms that glycyrrhizic acid (GL)—the core active component of licorice—and its metabolite glycyrrhetinic acid (GA) exhibit significant antiviral, antitumor, anti-inflammatory, and immunomodulatory activities.10–12 Mechanistic studies indicate that GL and GA can inhibit tumor cell proliferation and invasion by suppressing the activation of signaling pathways, including the nuclear factor-κB (NF-κB) pathway. They can also reverse multidrug resistance by downregulating P-glycoprotein expression. Furthermore, both compounds modulate the tumor immune microenvironment by promoting M1 macrophage polarization and enhancing cytotoxic T lymphocyte activity, providing a multitarget basis for synergistic cancer therapy.13,14 When combined with other chemotherapeutic agents, GL/GA significantly enhance therapeutic efficacy while mitigating toxic side effects. Concurrently, the inherent anti-inflammatory and antioxidant properties of GL/GA alleviate chemotherapy-induced inflammatory responses and oxidative damage, thereby protecting normal cellular functions. These mechanisms collectively provide both theoretical justification and practical pathways for achieving synergistic efficacy with reduced toxicity in GL/GA-based combination therapies. GL and its active metabolite GA also function as highly efficient targeting ligands. Crucially, they can specifically recognize the GA receptor (GA-R), which is overexpressed on the surfaces of cancer cells.14 GA-R expression is significantly upregulated, particularly in hepatocellular carcinoma cells. After GL is converted to GA in vivo, the resulting GA may facilitate active tumor targeting through receptor-mediated endocytosis.15 Leveraging this mechanism, conjugating them to nanocarriers significantly enhances drug accumulation at tumor sites, providing a precise strategy to reduce systemic toxicity and enhance anticancer efficacy. This specific receptor binding enables GL/GA to function as targeting moieties in actively targeted delivery systems. In addition, GL and GA serve as core self-assembling materials. Owing to their inherent amphiphilic molecular structures, they act as fundamental building blocks.16 Through ion pairing, metal coordination, hydrogen bonding, or hydrophobic interactions, they can spontaneously assemble into nanoparticles, micelles, or even three-dimensional hydrogel networks. Such “carrier-free” or “drug–carrier-integrated” systems not only simplify preparation processes but also combine multiple functions, including efficient drug loading, active targeting, and synergistic therapy.17 In summary, GL/GA have evolved from active molecules into multifunctional drug delivery components in the field of antitumor therapy. They integrate intrinsic therapeutic activity, specific targeting capabilities, and self-assembly properties, providing a robust platform for constructing integrated nanomedicines for synergistic therapy and precision delivery. These characteristics not only open new avenues for developing innovative anticancer formulations but also demonstrate the unique value and broad prospects of active ingredients derived from traditional Chinese medicine. GL/GA-based delivery systems have shown considerable promise in preclinical studies, but their clinical translation remains limited by poor formulation stability, difficulties in large-scale manufacturing, insufficient long-term safety data, and the lack of standardized evaluation criteria. As a result, many GL/GA-based nanomedicines, including actively targeted liposomes and in situ injectable hydrogels, still lack systematic assessment of their preclinical-to-clinical development, despite showing enhanced efficacy and reduced toxicity in receptor-rich tumors such as hepatocellular carcinoma. Recent reviews have discussed GL/GA from specific perspectives, including their antitumor mechanisms and liver-targeted delivery. Xiao et al18 summarized the role of GL-based nanosystems in regulating the tumor microenvironment, particularly in inhibiting angiogenesis and modulating immunosuppressive cells. Zhao et al19 and Stecanella et al20 focused on GL/GA as liver-targeting ligands and reviewed their applications in micelles, inclusion complexes, hydrogels, and related chemical modification strategies. However, these reviews mainly addressed individual functional roles, However, these reviews mainly focused on individual functional roles, leaving the design relationships and translational differences among these roles insufficiently explored. Therefore, a systematic and critical review of this field is needed. Based on these considerations, this review integrates the three functional roles of GL/GA into a unified framework. Relevant studies from the past six years were retrieved from PubMed, CNKI, and Web of Science using the keywords “glycyrrhizic acid”, “glycyrrhetinic acid”, “drug delivery systems”, “cancer therapy” and “tumor targeting” with selected relevant studies from 2015–2019 also included to support the proposed classification framework. This review summarizes the expanding roles of GL/GA from conventional bioactive agents to multifunctional delivery components, their applications across different delivery platforms, and the translational barriers and potential solutions for various formulation strategies. It aims to provide researchers with a comprehensive overview of GL/GA-based anticancer delivery systems and facilitate the future development of efficient and safe delivery strategies. GL/GA as Drug Delivery Systems GL and its aglycone GA are key bioactive components of the traditional Chinese medicinal herb licorice, exhibiting broad pharmacological activities that underpin their value in drug development. Extensive studies have demonstrated significant antitumor effects of GL and GA. They exert direct or indirect antitumor actions through multiple mechanisms, including inducing tumor cell apoptosis, inhibiting cell proliferation, arresting cell cycle progression, and suppressing angiogenesis.12 When combined with chemotherapeutic agents such as cisplatin, doxorubicin, and paclitaxel, GL and GA not only improve the pharmaceutical properties of these drugs but also enhance therapeutic efficacy through multi-target synergistic effects while mitigating toxic side effects. However, both compounds share common limitations, including low oral bioavailability and rapid metabolism in vivo. In addition, GA additionally faces the challenge of extremely poor water solubility, severely limiting the full realization of its clinical efficacy.10 To overcome these limitations, researchers have developed various nanodelivery systems. Based on different targeting strategies, these can be classified into three categories: passive targeting, active targeting, and stimuli-responsive delivery systems. These systems achieve precise delivery of GL/GA through the EPR effect, ligand-receptor recognition, and tumor microenvironment response, respectively, thereby significantly enhancing their efficacy and safety in cancer treatment (Table 1 and Figure 1). Table 1Glycyrrhizic Acid/Glyrrhetinic Acid as Drug Delivery SystemsMechanismDelivery SystemCharacterizationModelAdmin. RouteIn vivo ValidationYear, Ref.PassivetargetingGL PEG-LipSize: 110±2.05 nm;DL:8±0.41%;EE:61±0.81%;48 h sustained release (GL: 65%)In vitro (AGS/PC-3 cells)--202521GL/Cisplatin LPsSize: 81.6±3.3 nm;EE: GL (71.4±2.5%);Release rate: 24 h = ~29.85%In vitro (DLD-1/LIM-2405 cells)--202022AC-PCL (GL+PTX)-GNPsSize: 256.7±79.85 nm;EE(GL): 68.48±10.54%;DL(GL): 12.38±2.63%;96h sustained releaseIn vitro (HCT116/HT-29 cells)In vivo (DMH-induced colorectal lesion rats)P.O.AUC↑ (~4.38 fold);t1/2andMRT↑;Hepatic/renal markers normal; No hemolysis202523GL-LNPs Size: 196.75±3.58 nm;EE: 77.10±1.90%;DL: 21.02±1.05%;Release: 48 h sust.75.1%In vitro (MCF-7 cells)--202424PEG-Fmoc-GASize: 188.4±6.3 nm;CMC: 27.4 μg/mL;EE: 95.9%;DL: 7.3%In vitro (HepG2/4T1/A549 cells)In vivo (HepG2 xenograft mice)i.v.AUC↑, t1/2β↑, Vd↓, CL↓;Tumor volume↓;Survival 43d↑201925Active targetingLf-GL ConjugateLf-LfR ReceptorIn vitro (U87MG cells)In vivo (Orthotopic U87MG glioblastoma mice)i.v.AUC↑10-fold;Tumor volume↓32%;Survival↑87.5%;No systemic toxicity202326CpG-EXO/TGMTf-TfRIn vitro (GL261 cells)In vivo (Orthotopic GL261-Luc glioblastoma mice)i.v.t1/2↑;Tumor bioluminescence↓;MS↑29 days202327HA-CS-OGPsHA-CD44In vitro (HepG2 cells)--202428HA-GL-MT NFHA-CD44In vitro (KB/RAW 264.7 cells)In vivo (EAC-induced tumor-bearing mice)LocalapplicationTumor growth↓;No significant toxicity;Survival↑202429HA-GDT-LipHA-CD44In vitro (HepG2 cells)In vivo (HepG2 xenograft nude mice)i.v.Tumor inhibition↑;Systemic toxicity↓202230MDC-GA-PLMannose-MRIn vitro (HepG2 cells)In vivo (Kunming mice) toxicity/biodistributioni.v.Acute toxicity↓202231GA/FG-C18~ NMsGalactose-ASGP-RIn vitro (HepG2/MCF-7 cells)In vivo (Kunming mice) PK/biodistributioni.v.Tₑ↑10- fold;AUC0-24↑;MRT↑202032PD@TG-NanosBile acid-Bile acid receptor(putative)In vitro (HepG2 cells)In vivo (H22 tumor-bearing mice)i.v.TIR↑(63.30%);AUC/MRT/t1/2↑;No significant toxicity202333PR-lipo@GLPlatycodon/Ginsenoside-GLUTs (putative)In vitro (A549 cells)--202234GCMNPsWCM-mediated targetingIn vitro (AML/CRC cells)In vivo (AML/CRC tumor-bearing mice)i.v.Tumor growth↓;Survival↑202235GLNPs@COPTCM-OMVsIn vitro (H22/Hepa1-6 cells)In vivo (H22 tumor-bearing mice)i.v.Tumor growth↓;Reprograms TME (M1/M2↑);TEM/TCM↑202536EG@EMHMNPsErythrocyte-macrophage hybrid membraneIn vitro (B16 melanoma cells)--202337Stimuli responsiveM-DOX-GA NPsGSH-responsiveIn vitro (4T1 cells)In vivo (4T1 tumor-bearing mice)i.v.TIR: 77.37%;TUNEL cells↑;202138GL-DMOS@FeOOH NPsGSH-responsiveIn vitro (4T1 cells)In vivo (4T1 tumor-bearing mice)i.v.Tumor growth↓;HMGB1 release↓;Survival↑202539AS1411@Dox+GA/NPspH/GSH-responsiveIn vitro (HepG2, MCF-7 cells)In vivo (H22 and 4T1 breast cancer mice)i.v.Tumor-targeted accumulation↑;Tumor inhibition↑;Cardiotoxicity↓202540FCDL&DSF-SE@GpH/GSH-responsiveIn vitro (MGC-803 cells)In vivo (PC-bearing mice)i.p.Tumor inhibition↑352%;Tumor accumulation↑;No significant toxicity202441Note: ↑ and ↓ indicate increases and decreases, respectively, compared with control or reference groups.Abbreviations: EE, encapsulation efficiency; DL, drug loading; CMC, critical micelle concentration; AUC, area under the concentration–time curve; MRT, mean residence time; t1/2, half-life; Vd, volume of distribution; CL, clearance; TME, tumor microenvironment; HMGB1, high-mobility group box 1; TIR, tumor inhibition rate; MS, median survival; TEM, effector memory T cells; TCM, central memory T cells; P.O., oral administration; i.v., intravenous administration; i.p., intraperitoneal administration. Figure 1Schematic diagram of GL/GA-based DDS employing different targeting strategies for cancer therapy, with GA/GL as the core drugs delivered. Arrows indicate nanoparticle delivery pathways and stimuli-triggered drug release processes.The schematic diagram illustrates drug delivery systems for cancer therapy using glycyrrhizic acid and glycyrrhetinic acid. It is divided into three sections: Passive targeting, Ligand/antibody/cell membrane and Stimuli-responsive. Passive targeting includes PEG and EPR effect. Ligand/antibody/cell membrane features DCA, Tf, Lf, OMVs, WBCM, CMVs, CD44 and HA. Stimuli-responsive section shows GSH, pH and redox/pH mechanisms. The central part displays chemical structures of glycyrrhizic acid and glycyrrhetinic acid, surrounded by illustrations of nanoparticles and cells. A mouse is depicted in the stimuli-responsive section, indicating in vivo applications.GL/GA-based drug delivery systems with passive, active, and stimuli-responsive targeting strategies. Table 1Glycyrrhizic Acid/Glyrrhetinic Acid as Drug Delivery SystemsMechanismDelivery SystemCharacterizationModelAdmin. RouteIn vivo ValidationYear, Ref.PassivetargetingGL PEG-LipSize: 110±2.05 nm;DL:8±0.41%;EE:61±0.81%;48 h sustained release (GL: 65%)In vitro (AGS/PC-3 cells)--202521GL/Cisplatin LPsSize: 81.6±3.3 nm;EE: GL (71.4±2.5%);Release rate: 24 h = ~29.85%In vitro (DLD-1/LIM-2405 cells)--202022AC-PCL (GL+PTX)-GNPsSize: 256.7±79.85 nm;EE(GL): 68.48±10.54%;DL(GL): 12.38±2.63%;96h sustained releaseIn vitro (HCT116/HT-29 cells)In vivo (DMH-induced colorectal lesion rats)P.O.AUC↑ (~4.38 fold);t1/2andMRT↑;Hepatic/renal markers normal; No hemolysis202523GL-LNPs Size: 196.75±3.58 nm;EE: 77.10±1.90%;DL: 21.02±1.05%;Release: 48 h sust.75.1%In vitro (MCF-7 cells)--202424PEG-Fmoc-GASize: 188.4±6.3 nm;CMC: 27.4 μg/mL;EE: 95.9%;DL: 7.3%In vitro (HepG2/4T1/A549 cells)In vivo (HepG2 xenograft mice)i.v.AUC↑, t1/2β↑, Vd↓, CL↓;Tumor volume↓;Survival 43d↑201925Active targetingLf-GL ConjugateLf-LfR ReceptorIn vitro (U87MG cells)In vivo (Orthotopic U87MG glioblastoma mice)i.v.AUC↑10-fold;Tumor volume↓32%;Survival↑87.5%;No systemic toxicity202326CpG-EXO/TGMTf-TfRIn vitro (GL261 cells)In vivo (Orthotopic GL261-Luc glioblastoma mice)i.v.t1/2↑;Tumor bioluminescence↓;MS↑29 days202327HA-CS-OGPsHA-CD44In vitro (HepG2 cells)--202428HA-GL-MT NFHA-CD44In vitro (KB/RAW 264.7 cells)In vivo (EAC-induced tumor-bearing mice)LocalapplicationTumor growth↓;No significant toxicity;Survival↑202429HA-GDT-LipHA-CD44In vitro (HepG2 cells)In vivo (HepG2 xenograft nude mice)i.v.Tumor inhibition↑;Systemic toxicity↓202230MDC-GA-PLMannose-MRIn vitro (HepG2 cells)In vivo (Kunming mice) toxicity/biodistributioni.v.Acute toxicity↓202231GA/FG-C18~ NMsGalactose-ASGP-RIn vitro (HepG2/MCF-7 cells)In vivo (Kunming mice) PK/biodistributioni.v.Tₑ↑10- fold;AUC0-24↑;MRT↑202032PD@TG-NanosBile acid-Bile acid receptor(putative)In vitro (HepG2 cells)In vivo (H22 tumor-bearing mice)i.v.TIR↑(63.30%);AUC/MRT/t1/2↑;No significant toxicity202333PR-lipo@GLPlatycodon/Ginsenoside-GLUTs (putative)In vitro (A549 cells)--202234GCMNPsWCM-mediated targetingIn vitro (AML/CRC cells)In vivo (AML/CRC tumor-bearing mice)i.v.Tumor growth↓;Survival↑202235GLNPs@COPTCM-OMVsIn vitro (H22/Hepa1-6 cells)In vivo (H22 tumor-bearing mice)i.v.Tumor growth↓;Reprograms TME (M1/M2↑);TEM/TCM↑202536EG@EMHMNPsErythrocyte-macrophage hybrid membraneIn vitro (B16 melanoma cells)--202337Stimuli responsiveM-DOX-GA NPsGSH-responsiveIn vitro (4T1 cells)In vivo (4T1 tumor-bearing mice)i.v.TIR: 77.37%;TUNEL cells↑;202138GL-DMOS@FeOOH NPsGSH-responsiveIn vitro (4T1 cells)In vivo (4T1 tumor-bearing mice)i.v.Tumor growth↓;HMGB1 release↓;Survival↑202539AS1411@Dox+GA/NPspH/GSH-responsiveIn vitro (HepG2, MCF-7 cells)In vivo (H22 and 4T1 breast cancer mice)i.v.Tumor-targeted accumulation↑;Tumor inhibition↑;Cardiotoxicity↓202540FCDL&DSF-SE@GpH/GSH-responsiveIn vitro (MGC-803 cells)In vivo (PC-bearing mice)i.p.Tumor inhibition↑352%;Tumor accumulation↑;No significant toxicity202441Note: ↑ and ↓ indicate increases and decreases, respectively, compared with control or reference groups.Abbreviations: EE, encapsulation efficiency; DL, drug loading; CMC, critical micelle concentration; AUC, area under the concentration–time curve; MRT, mean residence time; t1/2, half-life; Vd, volume of distribution; CL, clearance; TME, tumor microenvironment; HMGB1, high-mobility group box 1; TIR, tumor inhibition rate; MS, median survival; TEM, effector memory T cells; TCM, central memory T cells; P.O., oral administration; i.v., intravenous administration; i.p., intraperitoneal administration. Glycyrrhizic Acid/Glyrrhetinic Acid as Drug Delivery Systems In vitro (AGS/PC-3 cells) In vitro (AGS/PC-3 cells) In vitro (DLD-1/LIM-2405 cells) In vitro (DLD-1/LIM-2405 cells) In vitro (HCT116/HT-29 cells) In vitro (HCT116/HT-29 cells) In vivo (DMH-induced colorectal lesion rats) In vivo (DMH-induced colorectal lesion rats) In vitro (MCF-7 cells) In vitro (MCF-7 cells) In vitro (HepG2/4T1/A549 cells) In vitro (HepG2/4T1/A549 cells) In vivo (HepG2 xenograft mice) In vivo (HepG2 xenograft mice) In vitro (U87MG cells) In vitro (U87MG cells) In vivo (Orthotopic U87MG glioblastoma mice) In vivo (Orthotopic U87MG glioblastoma mice) In vitro (GL261 cells) In vitro (GL261 cells) In vivo (Orthotopic GL261-Luc glioblastoma mice) In vivo (Orthotopic GL261-Luc glioblastoma mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (KB/RAW 264.7 cells) In vitro (KB/RAW 264.7 cells) In vivo (EAC-induced tumor-bearing mice) In vivo (EAC-induced tumor-bearing mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (HepG2 xenograft nude mice) In vivo (HepG2 xenograft nude mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (Kunming mice) toxicity/biodistribution In vivo (Kunming mice) toxicity/biodistribution In vitro (HepG2/MCF-7 cells) In vitro (HepG2/MCF-7 cells) In vivo (Kunming mice) PK/biodistribution In vivo (Kunming mice) PK/biodistribution In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (H22 tumor-bearing mice) In vivo (H22 tumor-bearing mice) In vitro (A549 cells) In vitro (A549 cells) In vitro (AML/CRC cells) In vitro (AML/CRC cells) In vivo (AML/CRC tumor-bearing mice) In vivo (AML/CRC tumor-bearing mice) In vitro (H22/Hepa1-6 cells) In vitro (H22/Hepa1-6 cells) In vivo (H22 tumor-bearing mice) In vivo (H22 tumor-bearing mice) In vitro (B16 melanoma cells) In vitro (B16 melanoma cells) In vitro (4T1 cells) In vitro (4T1 cells) In vivo (4T1 tumor-bearing mice) In vivo (4T1 tumor-bearing mice) In vitro (4T1 cells) In vitro (4T1 cells) In vivo (4T1 tumor-bearing mice) In vivo (4T1 tumor-bearing mice) In vitro (HepG2, MCF-7 cells) In vitro (HepG2, MCF-7 cells) In vivo (H22 and 4T1 breast cancer mice) In vivo (H22 and 4T1 breast cancer mice) In vitro (MGC-803 cells) In vitro (MGC-803 cells) In vivo (PC-bearing mice) In vivo (PC-bearing mice) Note: ↑ and ↓ indicate increases and decreases, respectively, compared with control or reference groups. Abbreviations: EE, encapsulation efficiency; DL, drug loading; CMC, critical micelle concentration; AUC, area under the concentration–time curve; MRT, mean residence time; t1/2, half-life; Vd, volume of distribution; CL, clearance; TME, tumor microenvironment; HMGB1, high-mobility group box 1; TIR, tumor inhibition rate; MS, median survival; TEM, effector memory T cells; TCM, central memory T cells; P.O., oral administration; i.v., intravenous administration; i.p., intraperitoneal administration. Schematic diagram of GL/GA-based DDS employing different targeting strategies for cancer therapy, with GA/GL as the core drugs delivered. Arrows indicate nanoparticle delivery pathways and stimuli-triggered drug release processes. Passive Targeting Nanodrug Delivery System Loaded with GL Passive targeting formulations are drug delivery systems that exploit the EPR effect to enable selective accumulation of nanocarriers in diseased tissues such as tumors or inflamed areas.42,43 Their practical application is constrained by physiological barriers, including tumor heterogeneity, high interstitial pressure, and dense stroma.44 Through carrier optimization, such as particle size control and PEGylation, therapeutic efficacy can be significantly enhanced.45 These formulations primarily include long-circulating liposomes, nanoparticles, and polymeric micelles, among others, which accumulate at tumor or inflammatory sites via the EPR effect to achieve drug delivery. GL-Loaded Long-Circulating Liposomes Liposomes are nano- or micron-sized vesicles composed of a phospholipid bilayer, with a hydrophilic aqueous core and a hydrophobic bilayer membrane. They can encapsulate both water-soluble and lipid-soluble drugs.46 Their excellent biocompatibility, degradability, and low toxicity make them important carriers in drug delivery systems. However, conventional liposomes are rapidly cleared by the mononuclear phagocyte system in vivo, resulting in short circulation times and limited targeting efficiency. Modification with polyethylene glycol (PEG) creates a “stealth” barrier on their surfaces, thereby reducing recognition by the immune system and significantly prolonging their circulation time in vivo.47 Haghighat et al21 constructed a GL-based PEGylated liposome (PEG-Lip) delivery system with a particle size of 110 ± 2.05 nm, a GL encapsulation efficiency of 61%, and controlled-release properties. The formulation achieved sustained release over 48 h, with a cumulative release of 65%. It significantly increased the proportion of late apoptotic cells and reduced the viability of PC-3 and AGS cells to 34% and 27.4%, respectively. Hatami et al22 developed PEGylated nanoliposomes co-loaded with cisplatin and GL, demonstrating significant synergistic antitumor effects in a colon cancer model. The formulation achieved a GL encapsulation efficiency of 71.4% and cumulative drug release below 40% within 24 h, markedly slower than that of the free drugs. In vitro, it reduced the IC50 in cisplatin-resistant DLD-1 colon cancer cells by 48% and increased DNA damage by 43%, demonstrating enhanced anticancer activity. Overall, these liposomal delivery systems commonly prolong the in vivo circulation of GL through PEGylation and show synergistic potential in reversing drug resistance. However, all studies remain limited to in vitro cellular models, lacking efficacy validation in tumor-bearing animals and systematic safety evaluation. GL-Loaded Nanoparticles Nanoparticles generally refer to solid or liquid particles with diameters ranging from 1 to 100 nm, exhibiting unique physicochemical properties. In the biomedical field, nanoparticles are widely used as drug carriers due to their small size, high specific surface area, and modifiability.48,49 Ansari et al23 developed amino cellulose-polycaprolactone-modified gelatin core-shell nanoparticles (AC-PCL(GL+PTX)-GNPs) for synergistic delivery of GL and paclitaxel (PTX) against DMH-induced colonic precancerous lesions. Compared with the free drugs, the formulation increased the AUC of GL by approximately 4.38-fold and prolonged its half-life. It also reduced precancerous lesions, restored colonic mucosal integrity, downregulated VEGF and Ki-67 expression, and activated caspase-9-mediated apoptosis. The system showed good biocompatibility without evident hepatic, renal, or tissue toxicity, indicating potential for enhanced efficacy and reduced toxicity. Srivastav et al24 developed EDC-crosslinked zein-based nanoparticles (GL-LNPs) for GL delivery against breast cancer, with a particle size of approximately 170 nm. The formulation enhanced cellular uptake and exhibited greater cytotoxic and pro-apoptotic effects than free GL. After treatment at 50 μg/mL for 48 h, cell viability decreased to approximately 40%, compared with 75% in the free GL group, while the apoptosis rates were 53.9% and 34.3%, respectively. Blank ZNPs showed no significant toxicity. Overall, nanoparticle formulations can improve the bioavailability and cellular uptake of GL/GA. Ansari et al23 preliminarily demonstrated the biocompatibility and safety of their formulation in rats. However, its long-term accumulation and metabolism remain unclear, whereas Srivastav et al24 conducted no in vivo studies. GA-Loaded Polymeric Micelles Polymeric micelles are core-shell structured nanoparticles formed by the self-assembly of amphiphilic block copolymers in water. Their hydrophobic segments aggregate to form a core for encapsulating poorly soluble drugs, while the hydrophilic segments extend outward to form a hydration shell. This significantly enhances drug solubility, stability, and in vivo targeted delivery efficiency.50,51 Yang et al25 developed PEG-Fmoc-GApolymeric prodrug micelles for the co-delivery of GA and doxorubicin (DOX) against hepatocel∞lular carcinoma. Compared with free DOX, the micelles significantly increased the AUC and elimination half-life of DOX, prolonged its circulation, enhanced tumor accumulation, and reduced cardiac distribution, suggesting potentially lower cardiotoxicity. In a HepG2 xenograft model, the formulation produced the strongest tumor growth inhibition and prolonged median survival to 43 days, compared with 38 days for free DOX, without evident body-weight loss. These findings demonstrate enhanced antitumor efficacy and improved safety. However, the study used a small subcutaneous xenograft model and lacked evaluation of GA disposition, active targeting, and long-term safety. Active Targeting Nanodrug Delivery System Loaded with GL/GA In cancer therapy, passive targeting formulations often face bottlenecks such as poor targeting, insufficient drug accumulation at tumor sites, and significant toxicity to normal tissues.52 In contrast, active targeting formulations promote the selective delivery and accumulation of GL/GA at tumor sites by modifying carrier surfaces with specific ligands (eg, proteins, glycans), that recognize receptors overexpressed on tumor cell surfaces or specific features of the tumor microenvironment. This strategy significantly enhances therapeutic efficacy while reducing systemic toxicity.53 Lactoferrin-Mediated Active Targeting The lactoferrin receptor is a transmembrane protein expressed on the surfaces of various cells and is highly expressed in blood–brain barrier endothelial cells and glioblastoma (GBM) cells.54 Furthermore, as a product of exocrine glands in multiple human sites, lactoferrin (Lf) effectively avoids first-pass hepatic metabolism, prolonging drug retention time.55 To overcome limitations in GBM targeting with GL, Kim et al26 developed a Lf-GL conjugate with a 1:10 molar ratio. Through LfR-mediated transport, Lf-GL crossed the blood–brain barrier, accumulated in GBM tissues, and inhibited HMGB1, a key damage-associated molecular pattern in the tumor microenvironment. Compared with free GL, Lf-GL increased the AUC by approximately 11.7-fold and brain accumulation by approximately twofold. In an orthotopic GBM mouse model, it reduced tumor volume by 32%, with 87.5% of mice surviving to day 28. Repeated administration caused no evident systemic toxicity or immune responses. This study highlights the core therapeutic role of GL as an HMGB1 antagonist. Coupling it with Lf achieves synergistic enhancement and reduced toxicity, offering a novel and highly effective strategy for targeting DAMP in GBM therapy. Transferrin-Mediated Active Targeting To support rapid proliferation, many cancer cells overexpress the transferrin receptor (TfR) to increase iron uptake. TfR is also abundant on endothelial cells of the blood–brain barrier/blood–brain tumor barrier (BBB/BBTB) and on GBM cells.56,57 Serum-derived exosomes (EXO) also express abundant TfR and can bind circulating transferrin (Tf), facilitating brain targeting.58 Cui et al27 developed CpG-EXO/TGM, a serum-exosome-coated TanIIA-GL self-assembled nanomicelle formulation carrying CpG oligonucleotides, for GBM chemoimmunotherapy. Binding of circulating Tf to exosomal TfR facilitated transcytosis across the BBB/BBTB and uptake by GBM cells. TanIIA and GL inhibited STAT3 phosphorylation and NF-κB p65 expression, respectively, thereby inducing tumor-cell apoptosis. CpG activated TLR9, promoted dendritic-cell maturation and M2-to-M1 macrophage polarization, and enhanced CD8+T-cell responses. In orthotopic GL261-Luc GBM-bearing mice, CpG-EXO/TGM showed the strongest tumor inhibition and extended the median survival to 29 days. Hyaluronic Acid-Mediated Active Targeting Hyaluronic acid (HA) can precisely recognize and bind to the overexpressed differentiation cluster receptor CD44 on the surface of cancer cells, enhancing drug accumulation at the tumor site, improving therapeutic efficacy, and reducing systemic toxicity.59–61 Chen et al28 developed a hyaluronic acid- and chitosan-modified phytosome-based composite nanocarrier (HA-CS-OGPs) for the co-delivery of oxymatrine (OMT) and GL against liver cancer. In HepG2 cells, HA-CS-OGPs showed greater cellular uptake than CS-OGPs and stronger cytotoxicity than free drugs and unmodified formulations. These effects were attributed to HA-CD44-mediated internalization and the MDR-modulating activity of GL. However, CD44-dependent uptake, ABC transporter inhibition, and intracellular OMT accumulation were not directly verified. Halder et al29 developed a hyaluronic acid nanofiber co-loaded with methotrexate (MT) and GL (GL-MT NF) for local oral cancer treatment. GL-MT NF reduced the IC50 in KB cells from 5 to 1.5 μg/mL and increased apoptosis from 41.92% to 63.97%. In mice, it also reduced pro-inflammatory cytokine levels and inflammatory-cell infiltration in the oral mucosa. However, the anticancer and in vivo mucositis experiments lacked a GL-only control, preventing confirmation of the independent contribution of GL and its synergy with MT. Chen et al30 developed HA-coated cationic liposomes (HA-GDT-Lip) carrying GDT, a mitochondria-targeted prodrug composed of GA, DOX, and triphenylphosphonium (TPP), for liver cancer therapy. HA-GDT-Lip enhanced mitochondrial DOX accumulation and increased ROS and caspase-3 activity to 3.9- and 3.2-fold the control levels, respectively. Its IC50 in HepG2 cells was 1.064 μg/mL, compared with 2.139 μg/mL for D-Lip. In HepG2 tumor-bearing mice, it inhibited tumor growth and alleviated DOX-induced weight loss and cardiac and hepatic injury. However, serum stability, biodistribution, and CD44-mediated targeting were not fully evaluated. Mannose-Mediated Active Targeting The mannose receptor (CD206), a C-type lectin receptor highly expressed on tumor-associated macrophages, serves as a target for reshaping the tumor immune microenvironment and enabling precise drug delivery. Mannose precisely recognizes and binds to CD206, which is highly expressed on M2 macrophages in the tumor microenvironment, thereby enhancing antitumor immune responses.62 Chen et al31 developed glycyrrhetinic acid proliposomes modified with the mannosylated ligand MDC (MDC-GA-PL) to improve GA solubility, storage stability, and liver-targeting potential. The formulation showed a uniform particle-size distribution, high encapsulation efficiency, and stability for six months at 6 ± 2 °C. Its 24-h IC50 in HepG2 cells was 47.68 μg/mL, compared with 61.15 μg/mL for GA-PL. The proportions of early and late apoptotic cells were 2.37- and 1.75-fold those observed with free GA, respectively. MDC modification did not significantly increase acute toxicity. However, no in vivo efficacy studies in disease models were conducted. Galactose-Mediated Active Targeting Fenugreek gum is a natural polysaccharide composed of polysaccharide chains formed by mannose and galactose units.63 Hepatocytes highly express the asialoglycoprotein receptor (ASGP-R) on their surface, which specifically recognizes and binds galactose or N-acetylgalactosamine.64 Zhou et al32 developed a GA nanomicelle delivery system (GA/FG-C18 NMs) based on stearic acid-modified fenugreek gum (FG-C18) for targeted therapy of hepatocellular carcinoma, aiming to enhance its water solubility and achieve efficient active liver targeting. Compared with free GA, the formulation increased the plasma AUC0-24h by approximately 1.7-fold and liver-targeting efficiency by approximately 10-fold. At 1 h after administration, the hepatic GA concentration was approximately 11-fold higher than that of free GA, while drug exposure in the spleen, lung, and brain was reduced. An in vitro galactose competition assay suggested that liver targeting was mediated by ASGPR recognition of the galactose residues in fenugreek gum. However, in vivo efficacy and safety were not evaluated in a liver cancer animal model. Deoxycholic Acid-Mediated Active Targeting Deoxycholic acid (DCA) is a secondary bile acid that can be recognized by bile acid transporters expressed on hepatocyte membranes, thereby conferring inherent liver-targeting properties on DCA-modified nanocarriers. Studies have shown that DCA-modified nanoparticles can be selectively taken up by hepatocytes through transporter-mediated mechanisms.65 Zong et al33 developed mPEG-DCA-based nanoself-assemblies co-loaded with tanshinone IIA (TAN) and GA (PD@TG-Nanos) for synergistic hepatoma therapy. TAN and GA showed the strongest synergy at a 1:1 mass ratio (CI = 0.415), while the formulation enhanced cellular uptake and increased their AUC by approximately 4.95- and 6.49-fold, respectively. In H22 tumor-bearing mice, PD@TG-Nanos achieved a tumor inhibition rate of 63.30% without evident short-term cardiac, hepatic, or renal injury. However, its hepatic targeting and synergistic mechanisms require further validation. Saponin-Mediated Active Targeting Liposomes are widely used in targeted drug delivery. Traditional liposomes rely on cholesterol to stabilize phospholipid bilayers, increase membrane rigidity, and prevent drug leakage.66 However, excessive cholesterol intake suppresses T-cell antitumor activity and impairs immune function in the tumor microenvironment.67 Saponins possess unique amphiphilic structures that not only replace cholesterol as liposome membrane stabilizers but also exhibit significant active targeting potential by specifically binding to tumor cell-overexpressed glucose transporters (GLUTs).68,69 Guo et al34 developed mixed saponin liposomes (PR-lipo) derived from the Platycodon grandiflorum–Glycyrrhiza uralensis herb pair, using ginsenoside and platycodin to replace cholesterol for GL delivery against lung cancer. The saponins may enhance tumor-cell uptake through GLUT-associated mechanisms, while platycodin may promote pulmonary accumulation. Compared with conventional cholesterol liposomes, PR-lipo@GL showed higher encapsulation efficiency and stronger cellular uptake, growth inhibition, and apoptosis induction in A549 cells, with an apoptosis rate of approximately 60%. Saponin-mediated targeting integrates the dual functions of carrier materials and targeting ligands, offering a distinct advantage in simplifying formulation design. However, the study was limited to in vitro experiments and lacked validation in animal models, as well as in vivo pharmacokinetic data (Figure 2). Figure 2The rational design of a multifunctional PR-lipo for targeted tumor therapy. Gray arrows indicate the preparation process of PR-lipo, whereas Orange arrows represent the administration and in vivo delivery pathway. Reproduced with permission from ref.34 Copyright © 2022 The Author(s). Licensed under CC BY 4.0.The diagram illustrates the preparation and delivery of PR-lipo for targeted tumor therapy. On the left, the preparation process is shown with gray arrows leading from herbal components to cholesterol liposome and P/R liposome. The P/R liposome is derived from Platycodon grandiflorum and Glycyrrhiza uralensis, using ginsenoside and platycodin. An orange arrow indicates the administration of PR-lipo into a mouse model. The pathway continues to the right, showing the in vivo delivery where liposomes travel through a blood vessel, interacting with tumor cells and tumor-associated macrophages. The diagram highlights the enhanced targeting and uptake of PR-lipo in tumor cells.Diagram of PR-lipo preparation and delivery for targeted tumor therapy, showing liposome types and in vivo pathway. The rational design of a multifunctional PR-lipo for targeted tumor therapy. Gray arrows indicate the preparation process of PR-lipo, whereas Orange arrows represent the administration and in vivo delivery pathway. Reproduced with permission from ref.34 Copyright © 2022 The Author(s). Licensed under CC BY 4.0. Membrane-Mimetic Technology for Targeted Delivery Cell membrane biomimetic technology involves coating synthetic nanocarriers with natural cell membranes to construct biofunctional drug delivery systems.70 By retaining the membrane proteins and functions of source cells, such as erythrocytes, leukocytes, and cancer cells, these systems can enhance tumor accumulation through homologous targeting, immune evasion, or inflammation-directed homing, thereby improving anticancer efficacy and reducing systemic toxicity.71 Li et al35 developed GA-loaded leukocyte membrane-coated PLGA nanoparticles (GCMNPs) to enhance immunotherapy for acute myeloid leukemia and colorectal cancer. The cell membrane coating improved immune evasion and tumor-homing capacity. GCMNPs induced ferroptosis by depleting GSH, suppressing GPX4, and increasing lipid peroxidation, while combination with ferumoxytol further enhanced iron-dependent cytotoxicity through the Fenton reaction. In AML and CRC mouse models, GCMNPs combined with ferumoxytol and anti-PD-L1 enhanced T-cell responses, suppressed tumor progression, and prolonged survival without evident systemic toxicity. However, only tissue distribution was evaluated, and pharmacokinetic parameters such as half-life and AUC were not reported. Zhao et al36 developed GLNPs@COP, GL-loaded PLGA nanoparticles coated with hybrid vesicles derived from bacterial outer membrane vesicles (OMVs) and tumor cell membrane vesicles (CMVs), for liver cancer chemoimmunotherapy. The hybrid membrane combined homologous tumor targeting with immune activation, while GL provided direct antitumor activity. GLNPs@COP remodeled the immunosuppressive microenvironment, enhanced CD8⁺T-cell responses, suppressed tumor growth, and prolonged survival without evident major-organ injury. However, pharmacokinetics and long-term immune safety were not evaluated. Cao et al37 developed erythrocyte-macrophage hybrid membrane-coated nanoparticles co-loaded with emodin and GL, termed EG@EMHM NPs. GL served as both a bioactive component and a solubilizing agent, increasing the aqueous solubility of emodin by approximately 7.22-fold and achieving an emodin encapsulation efficiency and loading capacity of 98.13% and 45.87%, respectively. Under 405nm irradiation, emodin-mediated photodynamic therapy induced apoptosis and senescence and inhibited migration in melanoma cells, demonstrating the potential of combining membrane-mediated targeting with photodynamic therapy. However, the experiments do not include in vivo data from any animal models (eg, tumor-bearing mice). Overall, cell membrane biomimetic strategies can improve the circulation, targeting, and immune-regulatory properties of GL/GA-based delivery systems, thereby enhancing tumor accumulation and therapeutic efficacy. However, their performance and safety depend on membrane source, protein integrity, coating efficiency, and batch variability. Current studies mainly focus on short-term efficacy, while systematic evaluations of pharmacokinetics, repeated-dose safety, and quality control remain limited. Stimuli-Responsive Targeting Nanodrug Delivery System Loaded with GL/GA Physicochemical targeted drug delivery systems based on tumor microenvironment-specific stimuli (eg, pH, glutathione) sense physiological-pathological differences between tumor sites and normal tissues. Upon specific microenvironmental signal activation, they achieve precise drug release, effectively addressing the toxic side effects of GL/GA on normal tissues while significantly enhancing the targeting and safety of antitumor therapy.72 GSH Responsive Systems Glutathione (GSH)-responsive systems represent a crucial “smart” design strategy, exploiting the substantial GSH concentration gradient between tumor and normal cells to achieve targeted controlled drug release. Tang et al38 developed GSH-responsive M-DOX-GA NPs based on an MPEG-PCL-DTDPA-DOX prodrug for the co-delivery of GA and DOX against breast cancer. The formulation achieved a GA encapsulation efficiency and drug loading of 89.28% and 18.22%, respectively, and released 80.43% of DOX and 64.70% of GA within 50 h under 10 mM GSH conditions. In 4T1 tumor-bearing mice, it achieved a tumor inhibition rate of 77.37% with low hepatic and renal toxicity. Reduced CUGBP1 and α-SMA expression suggested TME remodeling, although direct functional validation was lacking. Besides, Sha et al39 developed a GSH-responsive glycyrrhizic acid-loaded nanoplatform (GL-DMOS@FeOOH) consisting of a FeOOH core and a tetrasulfide-bridged mesoporous organosilica shell. Tumoral GSH triggered GL release and promoted Fe2+/ROS generation to induce ferroptosis, while GL inhibited HMGB1 and reduced MDSC infiltration. In 4T1 tumor-bearing mice, the platform suppressed tumor growth, enhanced CD8+ T-cell and dendritic-cell infiltration, and improved anti-PD-L1 therapy with favorable short-term biocompatibility (Figure 3). Figure 3In vivo immune activation and potent antitumor efficacy in combination with immune checkpoint blockade. (a) Immunofluorescence images showing the intracellular distribution of HMGB1 in 4T1 cells after different treatments (scale bar: 50 μm). (b) HMGB1 immunofluorescence staining of tumor sections from different treatment groups. (c) ELISA quantification of extracellular HMGB1 released from 4T1 cells after treatment with different nanoformulations. (d) Quantitative analysis of HMGB1 fluorescence intensity in tumor sections. (e) Representative flow cytometry plots of tumor-infiltrating MDSCs (CD11b+Gr-1+), including monocytic MDSCs and PMN-MDSCs, after different treatments. (f) Representative flow cytometry plots of tumor-infiltrating CD4+ and CD8+ T cells and mature dendritic cells (CD11c+CD80+CD86+). (g) Quantitative analysis of tumor-infiltrating MDSCs. (h) Quantitative analysis of tumor-infiltrating PMN-MDSCs. (i) Quantitative analysis of tumor-infiltrating CD8+ T cells. (j) Quantitative analysis of mature dendritic cells in tumor tissues (n = 3). (k) Tumor growth curves (n = 5). (l) Tumor weights (n = 5). (m) Survival curves of mice in the different treatment groups (n = 10). Data are presented as mean ± SD. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001.Reproduced with permission from ref.39 Copyright © 2025, The Author(s). Licensed under CC BY-NC-ND 4.0.The infographic compares Control, FeOOH, DMOS@FeOOH and GA-DMOS@FeOOH across various metrics: HMGB1 levels, immune infiltration, tumor growth, weight and survival. Immunofluorescence in 4T1 cells shows HMGB1 staining, with GA-DMOS@FeOOH having the lowest extracellular HMGB1 levels and fluorescence intensity. Flow cytometry plots reveal immune cell populations, with GA-DMOS@FeOOH showing reduced MDSCs and PMN-MDSCs, but increased CD8+ T cells and DCs. Tumor volume and weight are lowest with combined therapy, which also shows the highest survival probability. Key findings include GA-DMOS@FeOOH′s impact on immune infiltration and tumor metrics, with combined therapy offering the most significant benefits.Multi-panel infographic on HMGB1, immune cells, tumor growth and survival across four treatments. In vivo immune activation and potent antitumor efficacy in combination with immune checkpoint blockade. (a) Immunofluorescence images showing the intracellular distribution of HMGB1 in 4T1 cells after different treatments (scale bar: 50 μm). (b) HMGB1 immunofluorescence staining of tumor sections from different treatment groups. (c) ELISA quantification of extracellular HMGB1 released from 4T1 cells after treatment with different nanoformulations. (d) Quantitative analysis of HMGB1 fluorescence intensity in tumor sections. (e) Representative flow cytometry plots of tumor-infiltrating MDSCs (CD11b+Gr-1+), including monocytic MDSCs and PMN-MDSCs, after different treatments. (f) Representative flow cytometry plots of tumor-infiltrating CD4+ and CD8+ T cells and mature dendritic cells (CD11c+CD80+CD86+). (g) Quantitative analysis of tumor-infiltrating MDSCs. (h) Quantitative analysis of tumor-infiltrating PMN-MDSCs. (i) Quantitative analysis of tumor-infiltrating CD8+ T cells. (j) Quantitative analysis of mature dendritic cells in tumor tissues (n = 3). (k) Tumor growth curves (n = 5). (l) Tumor weights (n = 5). (m) Survival curves of mice in the different treatment groups (n = 10). Data are presented as mean ± SD. Statistical significance is indicated as *p < 0.05, **p < 0.01, and ***p < 0.001.Reproduced with permission from ref.39 Copyright © 2025, The Author(s). Licensed under CC BY-NC-ND 4.0. Overall, these GSH-responsive formulations exploit elevated GSH levels in tumors to trigger carrier disassembly and drug release, thereby enhancing the antitumor efficacy of GL/GA-based therapies through tumor cell killing and tumor microenvironment modulation. pH/Glutathione Dual-Response System The pH/glutathione dual-response system utilizes the tumor tissue’s characteristic acidic microenvironment (pH 5.4–6.8) and high glutathione concentration (several times higher than in normal cells) as triggering signals. It regulates photosensitizer release and activation through pH-sensitive chemical bonds (eg, pyridine bonds, ketal bonds) and glutathione-cleavable disulfide bonds.73 This dual-response mechanism significantly enhances drug accumulation and efficacy at the tumor site, offering a novel approach to improving drug targeting and safety. Hu et al40 developed an AS1411 aptamer-modified acid/GSH dual-responsive nanoprodrug (AS1411@Dox+GA/NPs) for the co-delivery of Dox and GA. In acidic endosomes, NaHCO3 generated CO2 to disrupt the nanoparticles and release GA and PLGA-ss-Dox, followed by GSH-mediated cleavage of disulfide bonds to liberate Dox in the cytoplasm. NaHCO3 also neutralized tumor acidity and increased Dox sensitivity. The formulation achieved tumor inhibition rates of approximately 93% and 82% in H22 and 4T1 models, respectively, while enhancing tumor accumulation and reducing cardiotoxicity. Similarly, Wang et al41 developed a thermosensitive hydrogel system (FCDL&DSF-SE@G) co-loaded with folate-targeted liposomes containing a Cu2+-diammonium glycyrrhizinate complex and a disulfiram submicroemulsion for intraperitoneal treatment of peritoneal carcinoma. Folate receptor-mediated uptake and intracellular acidity promoted Cu2+ release, while GSH converted DSF into DDTC, which chelated Cu2+ to form cytotoxic Cu(DDTC)2 and induced ROS-mediated apoptosis. In MGC-803 cells, the 72-h IC50 decreased from 1.33 to 0.42 μM. In a gastric cancer peritoneal dissemination model, the formulation increased tumor inhibition by 352% relative to free Cu2+/DSF, enhanced tumor retention, and caused no significant major-organ toxicity. Dual-responsive systems achieve precise spatiotemporal control of drug release through coordinated multiple stimuli, offering greater therapeutic efficacy than single-responsive systems but involving more complex carrier structures. In summary, GL/GA delivery systems mainly employ passive targeting, active targeting, and stimulus-responsive strategies. Passive targeting relies on the EPR effect to promote tumor accumulation, active targeting enhances tumor-cell uptake through ligand-receptor interactions involving folate, transferrin, or hyaluronic acid, and stimulus-responsive systems exploit low pH and elevated GSH levels for tumor-specific drug release. Although these strategies improve the pharmacokinetics and in vivo delivery efficiency of GL/GA, their efficacy as monotherapies remains limited, resulting in suboptimal antitumor effects. In recent years, studies have shown that GL/GA not only exert direct antitumor activity but also modulate the tumor immune microenvironment, for example through HMGB1 inhibition. Their co-delivery with chemotherapeutic agents such as DOX, cisplatin, and PTX, or with immunoadjuvants such as CpG, can produce multimechanistic synergy, enhancing efficacy while reducing toxicity. However, most current studies focus mainly on efficacy and toxicity, and the optimal component ratios, release sequences, and synergistic mechanisms require further investigation. Delivery Systems Utilizing GL/GA as Ligand Materials The rationale of GL/GA as liver cancer-targeting ligands lies in their ability to specifically recognize GA receptors overexpressed on hepatoma cell surfaces. Functional studies have confirmed that these sites are present on hepatoma cells, where their expression is 1.5- to 5-fold higher than in normal liver tissue, and that ligand binding mediates efficient endocytosis.74 However, the “GA receptor” is mainly inferred from binding and uptake studies, and its molecular identity and endocytic mechanism remain unclear.75 Nevertheless, based on existing functional evidence, various GA/GL-modified drug delivery systems have been developed to achieve selective accumulation in liver tumors through binding site-mediated endocytosis.76 Currently, the main GL/GA-based ligand-targeted delivery systems include liposomes, inorganic nanoparticles, metal-organic frameworks, micelles, polymeric nanoparticles, gels, and drug conjugates (Table 2 and Figure 4). Table 2Glycyrrhizic Acid/Glyrrhetinic Acid as Ligand Materials for Delivery SystemsDelivery SystemReceptorCharacteristicsModelTargeting BenefitYear, Ref.Dox&Ber@lip-GA GA-RTargeting TME via GA to inhibit CAFs-tumor crosstalkIn vitro (Huh-7+LX-2 co-culture)In vivo (H22+NIH-3T3 mice)IC50↓;Tumor accumulation↑1.6-fold;TIR: 90.82%↑202477GA-Dox/CuB-Lips GA-REnhanced Hepa1-6 targeting and uptake↑In vitro (Hepa1-6 cells)In vivo (Hepa1-6 ectopic/DEN-induced orthotopic mice)Cellular uptake↑;Apoptosis↑ ~70%;Tumor volume and weight↓202578Gly-Peg-Dox-ProLP-F6GA-RGA as targeting ligand and stabilizerIn vitro (HepG2/Mahlavu/Huh-7 cells)In vivo (HepG2 tumor-bearing mice) IC50↓ vs Caelyx® (1.14–1.5 fold);Toxicity↓1.86-fold;Tumor accumulation↑;Liver drug concentration↑2.48-fold202379GA/TAT-HCPT-LPGA-RLigand (GA + TAT cell-penetrating peptide)In vitro (HepG2 cells)In vivo (HepG2 xenograft)Cytotoxicity↓1.97-fold;Migration inhibition↑87.55%;Tumor growth↓202080GA-TAT-PYM-LGA-RLigand (GA + TAT cell-penetrating peptide)In vitro (HepG2 cells)In vivo (normal SD rats/normal KM mice)IC50↓;MRT & AUC↑2.79-fold;t1/2↑202281GA/RGD-DOX/ICG-LipsGA-R, αvβ3Dual targeting: GA-R + αvβ3In vitro (HepG2 cells)Cellular uptake↑202582GA/Fe3O4-PTX-LPGA-RGA + Magnetic (Fe3O4) targeting (with magnetic guidance)In vitro (HepG2 cells)In vivo (HepG2 xenograft) IC50↓;Cellular uptake↑93.15%;Tumor growth inhibition↑202183DOX-GA/PNA-LipsGA-R, MUC1GA targets hepatocytes; PNA targets overexpressed MUC1In vitro (SMMC-7721 cells)In vivo (SMMC-7721 xenograft)IC50↓;Tumor accumulation↑ (NIR imaging);TIR: 75.11%↑202084GA/FA-AMP-NLCGA-R, FA-RCo-modification with GA and FAIn vitro (HepG2 cells)In vivo (Hepa1-6 tumor-bearing mice)48h inhibition>single-ligand groups;TGI↑202585GL/LIP-CELGA-RGL replaces cholesterol in the liposomeIn vitro (BT549 breast cancer cells)IC50↑;Apoptosis↑~10-fold202586TP/GLLNPGA-RGL replaces cholesterol in the liposomeIn vitro (HepG2 cells)In vivo (H22 tumor-bearing mice)IC50↓;Cellular uptake↑;TIR: 87.21%202387GA/CLB-CSGA-RpH/Amidase; Responsiveness; GA: Improves Tumor Immune MicroenvironmentIn vitro (Hepa1-6/HepG2 cells)In vivo (Hepa1-6 tumor-bearing mice)IC50 (GA/CLB-CS)↓;Apoptosis rate ↑(78.08%);TIR: 55.57%↑202288DOX/GA-GEL GA-RGA active targeting; Gelatin matrix (MMP-2 enzyme degradation)In vitro (HepG2 cells)In vivo (H22 orthotopic liver cancer mice)IC50↓;Cell uptake↑;TIR: 76.9%↑201888Cela/GCTRGA-RGA active targeting; ROS responsiveness (thioketal linker); Rhein synergyIn vitro (HepG2, BEL-7402 cells)In vivo (H22 tumor-bearing mice)Cell proliferation↓;Medium/high dose tumor suppression↑;AUC↑3.08-fold202389GA/F127-SS-PDLA/CTDGA-RGA active targeting, 10% F127-GA optimal proportion; Reductive responsiveness (-SS-)In vitro (HepG-2 cells)IC50↓;Apoptosis rate↑ to 83.25%202490Ade/GA-HA NPsGA-RGA-modified hyaluronic acid nanoparticles, achieving GA-R-mediated liver-targeted deliveryIn vitro (HepG2/Bel-7402 cells)In vivo (HepG2 tumor-bearing nude mice)TIR: 67.89%↑, tumor weight↓;Ade concentration in liver tissue↑202091DTX/GA-HA NPsGA-R, CD44Dual targeting (GA + HA)In vitro (HepG2 cells)IC50↓;Apoptosis rate 24%↑202192ART/GA-PEG-PLGA NPsGA-RMain cellular uptake mechanisms are caveolin and macropinocytosis pathwaysIn vitro (HepG2 cells)In vivo (Hep3B-luc xenograft mice)Apoptosis rate↑;TIR: 81.99%↑;Survival period↑2023935-FU/GA-Thiolated NCsLRH-1Thiolated chitosan+thiolated Eudragit carrier: GA enhances liver targetingIn vitro (HepG2 cells)In vivo (DEN+CCl4 induced liver cancer rat model)IC50↓;Serum SGOT, ALP, total bilirubinlevels↓;Liver histopathology↑;5-FU concentration in liver homogenate↑202194GA-PPI/pDNAPolyplexesGA-RGA modification reduces PPI dendrimer toxicity and positive charge densityIn vitro (HepG2 cells)In vivo (HepG2 tumor-bearing nude mice)Transfection efficiency↑5.1-fold;Tumor growth↓;Survival rate↑202595CPT-PEG@MSN-DOX-GANPsGA-R pH-triggered release (hydrazone/imine bond); CPT prodrug (GSH responsive)In vitro (HepG2 cells)Selective internalization↑;Cell viability dropped to 17%2020965-FU@GA-MOFsNPsGA-RGA connected via 1,4-butanediamine long chain; pH-dependent releaseIn vitro (HepG2 cells)In vivo (KM mice)Drug accumulation in liver↑202097MIL-101-DOX/GA-CSNPsGA-R GA covalently linked to chitosan (CS);pH responseIn vitro (HepG2 cells)Cell uptake↑;Tumor inhibitory effect↑202398Pt (IV) Complex (Complex 20)GA-RGA targeting ligand+Pt (IV) prodrug axial modificationIn vitro (HepG2 cells)In vivo (BALB/c nude mice, HepG-2 xenograft mice)IC50↓;TIR: 72.9%202499Ir (III) Complex (Complex 1)GA-RGA-Ir (III) NIR theranosticsIn vitro (HepG2 cells)Cell uptake↑;Apoptosis↑2024100PEI-based Polyplex (PEI-GA/GL)GA-RGA/GL modified PEI 1.8 K;~60 nm nanocomplexIn vitro (HepG2 cells)In vivo (HepG2 peritoneal tumor mice)Transfection efficiency↑;Luciferase expression↑57-fold2019101GA-CurGA-RGA as targeting ligand;GSH-triggered gelationIn vitro (HepG2 cells)IC50↓;Cell uptake↑36%2017102GA-SS-LGGA-RGA-SS-Chol modified liposome;GSH-responsive releaseIn vitro (HepG2 cells)Cell uptake↑;2023103Note: ↑ and ↓ indicate increases and decreases, respectively, compared with the corresponding control, free drug, or non-targeted formulation groups.Abbreviations: GA-R, putative glycyrrhetinic acid-binding receptor/site; TME, tumor microenvironment; MUC1, mucin 1; FA-R, folate receptor; LRH-1, liver receptor homolog-1; NIR, near-infrared; IC50, half-maximal inhibitory concentration; TIR, tumor inhibition rate; AUC, area under the concentration–time curve; MRT, mean residence time; t1/2, half-life; SGOT, serum glutamic-oxalacetic transaminase; ALP, alkaline phosphatase. Figure 4Schematic illustration of GA-mediated active targeting of nanoparticles to tumor cells. GA-functionalized nanoparticles recognize putative GA-binding sites and undergo receptor-mediated endocytosis. Green symbols represent GA ligands, and purple symbols indicate putative GA-binding sites. Created in BioRender. (https://BioRender.com/nffm1ua).Diagram of GA-mediated targeting of nanoparticles to tumor cells via receptor-mediated endocytosis. Table 2Glycyrrhizic Acid/Glyrrhetinic Acid as Ligand Materials for Delivery SystemsDelivery SystemReceptorCharacteristicsModelTargeting BenefitYear, Ref.Dox&Ber@lip-GA GA-RTargeting TME via GA to inhibit CAFs-tumor crosstalkIn vitro (Huh-7+LX-2 co-culture)In vivo (H22+NIH-3T3 mice)IC50↓;Tumor accumulation↑1.6-fold;TIR: 90.82%↑202477GA-Dox/CuB-Lips GA-REnhanced Hepa1-6 targeting and uptake↑In vitro (Hepa1-6 cells)In vivo (Hepa1-6 ectopic/DEN-induced orthotopic mice)Cellular uptake↑;Apoptosis↑ ~70%;Tumor volume and weight↓202578Gly-Peg-Dox-ProLP-F6GA-RGA as targeting ligand and stabilizerIn vitro (HepG2/Mahlavu/Huh-7 cells)In vivo (HepG2 tumor-bearing mice) IC50↓ vs Caelyx® (1.14–1.5 fold);Toxicity↓1.86-fold;Tumor accumulation↑;Liver drug concentration↑2.48-fold202379GA/TAT-HCPT-LPGA-RLigand (GA + TAT cell-penetrating peptide)In vitro (HepG2 cells)In vivo (HepG2 xenograft)Cytotoxicity↓1.97-fold;Migration inhibition↑87.55%;Tumor growth↓202080GA-TAT-PYM-LGA-RLigand (GA + TAT cell-penetrating peptide)In vitro (HepG2 cells)In vivo (normal SD rats/normal KM mice)IC50↓;MRT & AUC↑2.79-fold;t1/2↑202281GA/RGD-DOX/ICG-LipsGA-R, αvβ3Dual targeting: GA-R + αvβ3In vitro (HepG2 cells)Cellular uptake↑202582GA/Fe3O4-PTX-LPGA-RGA + Magnetic (Fe3O4) targeting (with magnetic guidance)In vitro (HepG2 cells)In vivo (HepG2 xenograft) IC50↓;Cellular uptake↑93.15%;Tumor growth inhibition↑202183DOX-GA/PNA-LipsGA-R, MUC1GA targets hepatocytes; PNA targets overexpressed MUC1In vitro (SMMC-7721 cells)In vivo (SMMC-7721 xenograft)IC50↓;Tumor accumulation↑ (NIR imaging);TIR: 75.11%↑202084GA/FA-AMP-NLCGA-R, FA-RCo-modification with GA and FAIn vitro (HepG2 cells)In vivo (Hepa1-6 tumor-bearing mice)48h inhibition>single-ligand groups;TGI↑202585GL/LIP-CELGA-RGL replaces cholesterol in the liposomeIn vitro (BT549 breast cancer cells)IC50↑;Apoptosis↑~10-fold202586TP/GLLNPGA-RGL replaces cholesterol in the liposomeIn vitro (HepG2 cells)In vivo (H22 tumor-bearing mice)IC50↓;Cellular uptake↑;TIR: 87.21%202387GA/CLB-CSGA-RpH/Amidase; Responsiveness; GA: Improves Tumor Immune MicroenvironmentIn vitro (Hepa1-6/HepG2 cells)In vivo (Hepa1-6 tumor-bearing mice)IC50 (GA/CLB-CS)↓;Apoptosis rate ↑(78.08%);TIR: 55.57%↑202288DOX/GA-GEL GA-RGA active targeting; Gelatin matrix (MMP-2 enzyme degradation)In vitro (HepG2 cells)In vivo (H22 orthotopic liver cancer mice)IC50↓;Cell uptake↑;TIR: 76.9%↑201888Cela/GCTRGA-RGA active targeting; ROS responsiveness (thioketal linker); Rhein synergyIn vitro (HepG2, BEL-7402 cells)In vivo (H22 tumor-bearing mice)Cell proliferation↓;Medium/high dose tumor suppression↑;AUC↑3.08-fold202389GA/F127-SS-PDLA/CTDGA-RGA active targeting, 10% F127-GA optimal proportion; Reductive responsiveness (-SS-)In vitro (HepG-2 cells)IC50↓;Apoptosis rate↑ to 83.25%202490Ade/GA-HA NPsGA-RGA-modified hyaluronic acid nanoparticles, achieving GA-R-mediated liver-targeted deliveryIn vitro (HepG2/Bel-7402 cells)In vivo (HepG2 tumor-bearing nude mice)TIR: 67.89%↑, tumor weight↓;Ade concentration in liver tissue↑202091DTX/GA-HA NPsGA-R, CD44Dual targeting (GA + HA)In vitro (HepG2 cells)IC50↓;Apoptosis rate 24%↑202192ART/GA-PEG-PLGA NPsGA-RMain cellular uptake mechanisms are caveolin and macropinocytosis pathwaysIn vitro (HepG2 cells)In vivo (Hep3B-luc xenograft mice)Apoptosis rate↑;TIR: 81.99%↑;Survival period↑2023935-FU/GA-Thiolated NCsLRH-1Thiolated chitosan+thiolated Eudragit carrier: GA enhances liver targetingIn vitro (HepG2 cells)In vivo (DEN+CCl4 induced liver cancer rat model)IC50↓;Serum SGOT, ALP, total bilirubinlevels↓;Liver histopathology↑;5-FU concentration in liver homogenate↑202194GA-PPI/pDNAPolyplexesGA-RGA modification reduces PPI dendrimer toxicity and positive charge densityIn vitro (HepG2 cells)In vivo (HepG2 tumor-bearing nude mice)Transfection efficiency↑5.1-fold;Tumor growth↓;Survival rate↑202595CPT-PEG@MSN-DOX-GANPsGA-R pH-triggered release (hydrazone/imine bond); CPT prodrug (GSH responsive)In vitro (HepG2 cells)Selective internalization↑;Cell viability dropped to 17%2020965-FU@GA-MOFsNPsGA-RGA connected via 1,4-butanediamine long chain; pH-dependent releaseIn vitro (HepG2 cells)In vivo (KM mice)Drug accumulation in liver↑202097MIL-101-DOX/GA-CSNPsGA-R GA covalently linked to chitosan (CS);pH responseIn vitro (HepG2 cells)Cell uptake↑;Tumor inhibitory effect↑202398Pt (IV) Complex (Complex 20)GA-RGA targeting ligand+Pt (IV) prodrug axial modificationIn vitro (HepG2 cells)In vivo (BALB/c nude mice, HepG-2 xenograft mice)IC50↓;TIR: 72.9%202499Ir (III) Complex (Complex 1)GA-RGA-Ir (III) NIR theranosticsIn vitro (HepG2 cells)Cell uptake↑;Apoptosis↑2024100PEI-based Polyplex (PEI-GA/GL)GA-RGA/GL modified PEI 1.8 K;~60 nm nanocomplexIn vitro (HepG2 cells)In vivo (HepG2 peritoneal tumor mice)Transfection efficiency↑;Luciferase expression↑57-fold2019101GA-CurGA-RGA as targeting ligand;GSH-triggered gelationIn vitro (HepG2 cells)IC50↓;Cell uptake↑36%2017102GA-SS-LGGA-RGA-SS-Chol modified liposome;GSH-responsive releaseIn vitro (HepG2 cells)Cell uptake↑;2023103Note: ↑ and ↓ indicate increases and decreases, respectively, compared with the corresponding control, free drug, or non-targeted formulation groups.Abbreviations: GA-R, putative glycyrrhetinic acid-binding receptor/site; TME, tumor microenvironment; MUC1, mucin 1; FA-R, folate receptor; LRH-1, liver receptor homolog-1; NIR, near-infrared; IC50, half-maximal inhibitory concentration; TIR, tumor inhibition rate; AUC, area under the concentration–time curve; MRT, mean residence time; t1/2, half-life; SGOT, serum glutamic-oxalacetic transaminase; ALP, alkaline phosphatase. Glycyrrhizic Acid/Glyrrhetinic Acid as Ligand Materials for Delivery Systems In vitro (Huh-7+LX-2 co-culture) In vitro (Huh-7+LX-2 co-culture) In vivo (H22+NIH-3T3 mice) In vivo (H22+NIH-3T3 mice) In vitro (Hepa1-6 cells) In vitro (Hepa1-6 cells) In vivo (Hepa1-6 ectopic/DEN-induced orthotopic mice) In vivo (Hepa1-6 ectopic/DEN-induced orthotopic mice) In vitro (HepG2/Mahlavu/Huh-7 cells) In vitro (HepG2/Mahlavu/Huh-7 cells) In vivo (HepG2 tumor-bearing mice) In vivo (HepG2 tumor-bearing mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (HepG2 xenograft) In vivo (HepG2 xenograft) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (normal SD rats/normal KM mice) In vivo (normal SD rats/normal KM mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (HepG2 xenograft) In vivo (HepG2 xenograft) In vitro (SMMC-7721 cells) In vitro (SMMC-7721 cells) In vivo (SMMC-7721 xenograft) In vivo (SMMC-7721 xenograft) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (Hepa1-6 tumor-bearing mice) In vivo (Hepa1-6 tumor-bearing mice) In vitro (BT549 breast cancer cells) In vitro (BT549 breast cancer cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (H22 tumor-bearing mice) In vivo (H22 tumor-bearing mice) In vitro (Hepa1-6/HepG2 cells) In vitro (Hepa1-6/HepG2 cells) In vivo (Hepa1-6 tumor-bearing mice) In vivo (Hepa1-6 tumor-bearing mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (H22 orthotopic liver cancer mice) In vivo (H22 orthotopic liver cancer mice) In vitro (HepG2, BEL-7402 cells) In vitro (HepG2, BEL-7402 cells) In vivo (H22 tumor-bearing mice) In vivo (H22 tumor-bearing mice) In vitro (HepG-2 cells) In vitro (HepG-2 cells) In vitro (HepG2/Bel-7402 cells) In vitro (HepG2/Bel-7402 cells) In vivo (HepG2 tumor-bearing nude mice) In vivo (HepG2 tumor-bearing nude mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (Hep3B-luc xenograft mice) In vivo (Hep3B-luc xenograft mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (DEN+CCl4 induced liver cancer rat model) In vivo (DEN+CCl4 induced liver cancer rat model) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (HepG2 tumor-bearing nude mice) In vivo (HepG2 tumor-bearing nude mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (KM mice) In vivo (KM mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (BALB/c nude mice, HepG-2 xenograft mice) In vivo (BALB/c nude mice, HepG-2 xenograft mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (HepG2 peritoneal tumor mice) In vivo (HepG2 peritoneal tumor mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) In vitro (HepG2 cells) Note: ↑ and ↓ indicate increases and decreases, respectively, compared with the corresponding control, free drug, or non-targeted formulation groups. Abbreviations: GA-R, putative glycyrrhetinic acid-binding receptor/site; TME, tumor microenvironment; MUC1, mucin 1; FA-R, folate receptor; LRH-1, liver receptor homolog-1; NIR, near-infrared; IC50, half-maximal inhibitory concentration; TIR, tumor inhibition rate; AUC, area under the concentration–time curve; MRT, mean residence time; t1/2, half-life; SGOT, serum glutamic-oxalacetic transaminase; ALP, alkaline phosphatase. Schematic illustration of GA-mediated active targeting of nanoparticles to tumor cells. GA-functionalized nanoparticles recognize putative GA-binding sites and undergo receptor-mediated endocytosis. Green symbols represent GA ligands, and purple symbols indicate putative GA-binding sites. Created in BioRender. (https://BioRender.com/nffm1ua). GL/GA-Modified Liposomes GL/GA-modified liposomes are among the most extensively investigated liver-targeted delivery systems and have been successfully used to deliver various antitumor agents (such as Murrayafoline A,75 curcumin,76 docetaxel,104 paeoniflorin,105 and doxorubicin,79), achieving precise liver-targeted therapy. These formulations can markedly enhance hepatic targeting and cellular uptake. For example, Xu et al77 constructed GA- targeted liposomes co-loaded with Dox and berberine for liver cancer targeting. Their uptake efficiency in Huh-7 cells was 2.77 times that of free Dox and 1.6 times that of unmodified liposomes (Dox@lip), achieving a tumor inhibition rate as high as 90.82%. However, the study lacked a non-GA targeting-ligand control and a free-GA competition assay, preventing confirmation that the enhanced tumor accumulation was specifically mediated by GA-binding sites. Chen et al78 constructed GA-modified liposomes co-loaded with doxorubicin and cucurbitacin B for liver cancer treatment. In vitro, they exhibited strong cytotoxicity against Hepa1-6 liver cancer cells with an IC50 as low as 4.6±0.5 nM, significantly outperforming non-targeted liposomes and free drug combinations. Nevertheless, the study lacked a free-GA competition assay and optimization of ligand density, and the cucurbitacin B loading was relatively low at 0.4%. Similarly, Diril et al77 reported that GA-modified doxorubicin proliposomes produced hepatic drug concentrations 2.48-fold higher than those of the commercial formulation Caelyx® while reducing cardiotoxicity. Collectively, these studies demonstrate that GA-modified liposomes can improve hepatic targeting, antitumor efficacy, and safety. To improve delivery precision, multiligand strategies have combined GL/GA with cell-penetrating peptides, RGD peptides, or magnetic nanomaterials to construct multifunctional nanoplatforms. For example, Huang et al80 developed GA- and TAT-modified 10-hydroxycamptothecin liposomes (GA/TAT-HCPT-LP) for liver cancer therapy. The formulation showed an IC50 of 25.7 μg/mL in HepG2 cells and effectively inhibited cell migration and induced apoptosis. However, the absence of a free-GA competition assay limited confirmation of GA-mediated specific targeting. Li et al81 reported that GA/TAT-modified pingyangmycin liposomes increased the mean residence time and AUC by approximately 2.79- and 2.45-fold, respectively. Zhang et al82 developed GA/RGD-modified liposomes co-loaded with DOX and indocyanine green (ICG) for combined chemo-phototherapy. The formulation enhanced uptake by HepG2 cells and reduced cell viability to 5.56%, outperforming monotherapy and non-targeted formulations. However, no in vivo studies were conducted. Zhao et al83 developed GA/Fe3O4 co-modified paclitaxel nanoliposomes for combined active and magnetic targeted therapy of liver cancer. The formulation showed enhanced proliferation inhibition, migration suppression, and apoptosis induction in HepG2 cells. In vivo, it achieved superior tumor accumulation and significantly inhibited tumor growth with no obvious toxicity to major organs. However, no GA competition assay was performed. Furthermore, Li et al84 constructed GA- and PNA-co-modified doxorubicin liposomes that specifically recognized MUC1-positive hepatocellular carcinoma cells, reducing the IC50 value to 7.4 ng/mL. In vivo, tumor inhibition rates reached 75.11% with significantly reduced toxicity. Mai et al85 constructed GA-folate co-modified nanostructured lipid carriers, which demonstrated superior tumor targeting and antitumor efficacy compared to monomodified carriers both in vitro and in vivo. These multivalent ligand modification strategies synergistically enhance drug targeting precision, antitumor efficacy, and therapeutic safety through distinct mechanisms. Moreover, GL can function directly as a structural component of liposomes. For instance, Zhang et al86 developed GL-modified celastrol liposomes for targeted and safer breast cancer therapy by completely replacing cholesterol with GL as both a membrane stabilizer and functional component. The formulation induced 40.87% apoptosis in BT549 cells, significantly outperforming unmodified liposomes, suggesting that GL improved drug delivery to tumor cells (Figure 5). However, these findings were based solely on in vitro experiments and lacked in vivo validation. Xue et al87 similarly replaced cholesterol with GL to construct triptolide-loaded GL lipid nanoparticles (TP/GLLNPs) for combined immunochemotherapy of liver cancer. Compared with free triptolide and conventional liposomes, TP/GLLNPs enhanced HepG2 cellular uptake and showed greater cytotoxicity, with an IC50 of 4.6 nM versus 6.6 nM for TP/Lipo. The formulation activated cleaved PARP and caspase-3/9-mediated apoptosis, achieved a tumor inhibition rate of 87.21%, and promoted M2-to-M1 polarization of tumor-associated macrophages. However, the in vivo immune activation was not supported by functional indicators such as IL-10 and TNF-α. Figure 5(A) JC-1 fluorescence staining analysis of mitochondrial membrane potential alterations in BT549 cells after different treatments. Scale bar: 20 μm. (B) Quantification of the JC-1 aggregate/monomer fluorescence intensity ratio. (C) Flow cytometry analysis of apoptosis in BT549 cells treated with LIP-CEL, GL/LIP-CEL, and Free-CEL. (D) Quantitative analysis of apoptotic cells based on flow cytometric results. Data are presented as mean ± SD (n = 3). *P < 0.05. Reproduced with permission from ref.86 Copyright © 2025 Zhang, Li, Gao, Liu, Liang and Yue.Licensed under CC BY 4.0.The image consists of four panels analyzing BT549 cells. A) JC-1 fluorescence staining shows mitochondrial membrane potential alterations with columns labeled JC-1 aggregate, JC-1 monomer, Hoechst 33342 and Merge. Rows represent Control, LIP-CEL, GA/LIP-CEL and Free-CEL treatments. B) A bar graph displays the JC-1 aggregate/monomer fluorescence intensity ratio for Control, LIP-CEL, GA/LIP-CEL and Free-CEL, with a significant difference marked by an asterisk. C) Flow cytometry plots show apoptosis analysis with quadrants labeled Q1 to Q4, indicating different cell populations.D) A bar graph illustrates cell apoptotic rates for Control, LIP-CEL, GA/LIP-CEL and Free-CEL, with statistical significance indicated by an asterisk.Four-panel analysis of JC-1 staining, fluorescence intensity, flow cytometry and apoptosis in BT549 cells. (A) JC-1 fluorescence staining analysis of mitochondrial membrane potential alterations in BT549 cells after different treatments. Scale bar: 20 μm. (B) Quantification of the JC-1 aggregate/monomer fluorescence intensity ratio. (C) Flow cytometry analysis of apoptosis in BT549 cells treated with LIP-CEL, GL/LIP-CEL, and Free-CEL. (D) Quantitative analysis of apoptotic cells based on flow cytometric results. Data are presented as mean ± SD (n = 3). *P < 0.05. Reproduced with permission from ref.86 Copyright © 2025 Zhang, Li, Gao, Liu, Liang and Yue.Licensed under CC BY 4.0. GA-Modified Micelles In GA-based liver-targeted drug delivery systems, GA not only serves as a targeting head to mediate efficient drug accumulation in tumor tissues but also synergistically reverses the immunosuppressive microenvironment through its inherent immunomodulatory functions. By further incorporating smart release mechanisms such as ROS-responsive or reduction-sensitive delivery, precise and controllable drug release within the tumor microenvironment can be achieved. This approach synergistically enhances antitumor efficacy while significantly reducing systemic toxicity.18 Sang et al88 developed GA-modified chlorambucil-chitosan prodrug micelles (GA/CLB-CS) for hepatocellular carcinoma treatment. The micelles release CLB in response to the tumor microenvironment, inducing G2/M arrest via p21, cyclin B1, and CDK1 modulation, and activating the p53-Bax-Caspase pathway to promote apoptosis. GA concurrently enhanced CD4⁺ and CD8⁺ T cell infiltration and reduced Treg/Th2 subsets, counteracting CLB-induced immunosuppression. The system achieved active tumor targeting, extended plasma half-life from 3.08 to 6.54 hours, and increased tumor inhibition rate to 55.57% (free drug: 15.70%), with no significant toxicity to major organs. However, the study lacked a comparative serum stability assessment of GA-modified and unmodified micelles, which warrants further investigation. Fan et al106 reported the synthesis of GA-gelatin micelles loaded with doxorubicin (DOX/GA-GEL) for hepatocellular carcinoma treatment. Pharmacodynamic experiments indicated that the tumor inhibition rate of DOX/GA-GEL-2 (76.9%) was higher than that of free DOX (65.3%), while reducing cardiac and renal toxicity. However, DOX/GA-GEL micelles exhibited a burst release effect, releasing 39.5% within 8 hours and 41.7% within 72 hours in PBS (pH 7.4). This rapid release may lead to excessively high peak plasma concentrations, increasing systemic toxicity risks, and hindering sustained therapeutic effects. Furthermore, combining the natural liver-targeting ability of GA with intelligent response-driven drug delivery mechanisms enhances therapeutic precision. Zhang et al89 developed ROS-responsive Cela/GCTR micelles for celastrol delivery. The micelles remained stable in the bloodstream but rapidly released the drug in ROS-rich tumors, enhancing cellular uptake and in vivo targeting, with a targeting efficiency of 2.07% and a 3.08-fold increase in AUC. They also showed enhanced antitumor activity and low toxicity. However, the GA substitution degree was only approximately 2% and was not systematically optimized. Hu et al90 developed GA-modified reduction-responsive mixed micelles (GA/F127-SS-PDLA/CTD) by combining F127-GA and F127-SS-PDLA at a 1:9 ratio. The micelles released 74.36% of cantharidin within 24 h under high-GSH conditions while remaining stable under physiological conditions. They improved cellular uptake and pharmacokinetics and reduced the IC50 to 0.732 μg/mL, although their in vivo efficacy requires further validation. GA-Modified Nanoparticles Nanoparticles modified with GA significantly enhance drug targeting efficiency to the liver through GA’s specific binding to receptors on hepatocellular carcinoma cell surfaces. This approach not only boosts antitumor efficacy but also effectively reduces systemic toxicity. Current research encompasses not only chemotherapeutic agents (eg, docetaxel, doxorubicin) and gene carriers but also extends into the field of diagnosis-therapy integration, successfully applied to various nanocarrier systems, including polymers, mesoporous silica, and metal-organic frameworks (MOFs). Polymeric Nanoparticles Wu et al91 constructed GA-modified HA nanoparticles (Ade/GA-HA NPs) for liver-targeted delivery of adenosine (Ade). Compared to free Ade, Ade/GA-HA NPs more effectively inhibited hepatocellular carcinoma cell proliferation and migration while inducing apoptosis (apoptosis rate increased from 4.87% to 19.96%). In vivo pharmacokinetics revealed a 3.7-fold higher hepatic drug concentration compared to free drug, significantly inhibiting tumor growth without causing hemolytic toxicity. Further, XUE et al92 developed docetaxel-loaded nanoparticles using the GA-HA carrier (DTX/GA-HA-NPs), which were employed for the treatment of hepatocellular carcinoma. The DTX/GA-HA-NPs IC50 value decreased by approximately 73% compared to free docetaxel, while the apoptosis rate increased to 24%. These results highlight the advantage of GA modification in enhancing the efficacy of chemotherapeutic drugs. A major limitation of this study is its reliance on in vitro cellular models, which lack critical in vivo animal experiments to validate targeting and therapeutic efficacy. PAN et al93 developed GA-modified PEG-PLGA nanoparticles loaded with artemisinin (ART/GA-PEG-PLGA NPs) for HCC treatment. Pharmacokinetic data demonstrated approximately 5-fold higher AUC0-∞ compared to free artemisinin, with mean residence time (MRT) extended to 5.54 hours. In vivo distribution revealed enhanced hepatic accumulation, achieving an 81.99% tumor inhibition rate. Histopathological analysis confirmed favorable safety profiles. However, its long-term biosafety, targeting mechanism, and clinical translational value still require further validation. Bhat et al94 further developed a nanocomposite using thiolated chitosan and thiolated Eudragit functionalized with GA for targeted delivery of 5-fluorouracil (5-FU) in hepatocellular carcinoma. In a DEN-induced rat HCC model, the nanoparticles significantly reduced serum ALT and AST levels and improved liver histopathology. Notably, the blank nanocarrier (without 5-FU) also exhibited therapeutic effects, suggesting inherent anti-HCC activity of GA. However, the study lacks systematic pharmacokinetic data. Wang et al95 extended GA’s application to gene therapy by using glycyrrhetinic acid-modified polyamide-amine (PPI) dendrimers (GA-PPI) as gene carriers to deliver plasmid DNA (pDNA) for targeted gene therapy against liver cancer. The high cytotoxicity of unmodified PPI stems from its excessively high positive charge density on the surface, which, while beneficial for DNA compaction, also causes non-specific damage to normal cell membranes. GA conjugation reduced surface positive charge, significantly decreasing cytotoxicity while enhancing transfection efficiency by 5.1-fold compared to unmodified PPI. In tumor-bearing mice, GA-PPI-3/pDNA complexes upregulated p53 expression, induced apoptosis, and suppressed tumor growth with minimal systemic toxicity, as confirmed by histopathology. However, systematic pharmacokinetic studies (eg, blood clearance, tissue distribution, half-life) were lacking. Mesoporous Silica Nanoparticles As an inorganic nanomaterial, mesoporous silica nanoparticles possess a highly ordered mesoporous structure, extremely high specific surface area, and easily functionalizable surfaces, enabling efficient loading of various drug molecules. Their surfaces readily undergo chemical modification, allowing flexible conjugation of GA for precise delivery. Furthermore, the stable inorganic framework not only effectively protects the drug but also exhibits excellent biocompatibility.107 Martínez-Edo et al96 developed GA-modified mesoporous silica nanoparticles for the co-delivery of DOX and CPT-PEG against HCC. pH-sensitive imine bonds enabled tumor-activated targeting, while hydrazone and disulfide bonds provided dual-responsive drug release. GA modification increased HepG2 uptake by 73% and achieved a HepG2/HeLa selectivity ratio of 9:1, enhancing synergistic cytotoxicity and reducing nonspecific toxicity. However, the study lacked in vivo pharmacokinetic, biodistribution, and efficacy validation. Metal-Organic Framework Nanoparticles Metal-organic framework (MOF) nanoparticles are novel porous nanomaterials formed by linking metal ions with organic molecules, exhibiting a high specific surface area and tunable pore structures. Their adjustable pore sizes and surface chemistry enable efficient loading and controlled release of various therapeutic agents, including small molecules and proteins.108 Furthermore, the abundant active sites on MOF surfaces facilitate modification with GA, endowing the nanocarriers with the ability to actively target specific tissues or cells. Li et al97 utilized GA-modified metal-organic frameworks (GA-MOFs) for delivering 5-fluorouracil (5-FU) to treat liver cancer. This system demonstrated significantly enhanced inhibitory activity against HepG2 cells in vitro; in vivo experiments further confirmed its targeting advantage:0.5 hours post-administration, the intrahepatic drug concentration in the 5-FU@GA-MOFs group reached 79.79 μg/mL, nearly double that of the free drug group—with prolonged retention time. In vivo imaging visually validated its superior hepatic targeting, effectively enhancing drug accumulation at the lesion site to boost efficacy while reducing systemic side effects. Similarly. Cui et al98 developed iron-based MOF nanoparticles (MIL-101-DOX/GA-CS) with a chitosan (CS)-functionalized coating and GA modification for DOX delivery in liver cancer treatment. Studies confirmed that these nanoparticles not only exhibit high drug loading capacity but also enable rapid and substantial drug release under acidic conditions (pH 5.5) simulating the tumor microenvironment, while releasing slowly at physiological pH. In vitro experiments demonstrated significant cytotoxic effects of the loaded nanoparticles on HepG2 cells. GA-mediated enhancement of cellular uptake, penetration, and killing capacity in more complex 3D tumor spheroid models highlights its potential as an efficient, targeted delivery system. However, both studies suffer from “lack of in vivo efficacy validation” and “inadequate biosafety assessment”. GL/GA-Modified Conjugates Unlike complex nanoparticles requiring drug encapsulation, both the carboxyl groups and hydrophobic regions within the GL/GA molecular structure are amenable to functionalization. Through covalent bonding with chemotherapeutic agents, metal complexes, and gene carriers, structurally defined, functionally integrated monomolecular conjugate systems can be constructed. Such conjugates not only retain the specific recognition capability of GL/GA for receptors highly expressed on hepatocyte membranes but also enable multifunctional synergistic effects—such as drug delivery and therapeutic activation—through rational design.109 Platinum-based drugs, particularly cisplatin, are widely used chemotherapeutic agents that induce DNA damage but are limited by systemic toxicity, poor targeting, and drug resistance.110,111 To overcome these shortcomings, Huang et al99 coupled GA with platinum drugs (cisplatin) to synthesize a series of platinum (IV) prodrugs (represented by complex 20) for hepatocellular HCC treatment. This complex exhibits multi-pathway synergistic anticancer effects: the released active platinum component induces DNA cross-linking damage, while the GA component enhances therapeutic efficacy through multiple pathways, including mitochondrial dysfunction, endoplasmic reticulum stress, and ferroptosis. In HepG-2 xenografts, complex 20 achieved a tumor inhibition rate of 72.9%, outperforming cisplatin (61.8%) and the physical mixture of cisplatin with GA (68.9%), while exhibiting favorable in vivo safety. These results highlight the advantages of GA-targeted ligands in enhancing efficacy, overcoming resistance, and reducing toxicity. Iridium (III) complexes possess favorable photophysical properties, including near-infrared emission, long-lived phosphorescence, and high photostability, and are widely used in bioimaging and photodynamic therapy. However, their clinical application remains limited by poor targeting and systemic toxicity.112,113 Based on this, Wang et al100 developed a GA-conjugated iridium (III) complex (complex 1) as a dual-functional theranostic probe for HCC. Mechanistically, it induced mitochondrial MPTP opening, ROS burst, and Bax/Bcl-2 imbalance, activating the mitochondrial apoptosis pathway. Complex 1 exhibited potent cytotoxicity against HepG2 cells (IC50 = 1.26 μM), significantly outperforming free GA (39.81 μM) and the non-targeted complex 2 (3.47 μM). However, the study lacks in vivo efficacy validation and systematic evaluation of biodistribution, metabolism, and long-term biosafety. Beyond small-molecule drugs, GA/GL are also utilized in constructing gene delivery systems to address the low transfection efficiency and poor targeting of non-viral vectors. Cao et al101 developed polyethyleneimine (PEI) polymer gene delivery conjugates modified with GA or GL for targeted gene therapy in HCC. GA/GL modification reduced PEI cytotoxicity and markedly enhanced gene transfection. In HepG2 cells, the PEI-GL1 0.62/pDNA formulation achieved 10.2-fold higher gene expression than PEI 25K. This effect was significantly inhibited by free GA, suggesting GA-binding site-mediated uptake. In a HepG2 intraperitoneal tumor model, its gene expression efficiency was 57-fold higher than that of unmodified PEI and showed favorable tumor targeting (Figure 6). However, the study did not further evaluate the in vivo antitumor efficacy of a therapeutic gene delivered by this system. Figure 6Transfection mechanisms of GA and GL modified PEIs. The “+” symbols indicate electrostatic interactions, and the blue arrows represent nanocomplex formation, self-assembly, and intracellular delivery processes. The negative signs on DNA indicate its negative charge. Reproduced with permission from ref.101 Copyright © 2019 by the authors. Licensee MDPI, Basel, Switzerland. Licensed under CC BY 4.0.The diagram illustrates the transfection mechanisms of GA and GL modified polyethyleneimines, or PEIs. On the left, the structure of PEI is shown, followed by GL1 and GA molecules. Below, PEI is combined with GL1 to form PEI-GL1 and with GA to form PEI-GA. To the right, DNA is depicted with negative signs indicating its charge. The DNA interacts with PEI-GL1 and PEI-GA, leading to self-assembly into nanocomplexes measuring 50 to 60 nanometers. Further to the right, these complexes are shown forming an artificial virus. The process involves receptor-mediated endocytosis and energy-independent transduction, as indicated by the text. The artificial virus is depicted entering a cell through caveolae and clathrin-independent endocytosis, with the cell membrane and internal structures visible.A diagram showing transfection mechanisms of GA and GL modified PEIs with DNA and artificial virus formation. Transfection mechanisms of GA and GL modified PEIs. The “+” symbols indicate electrostatic interactions, and the blue arrows represent nanocomplex formation, self-assembly, and intracellular delivery processes. The negative signs on DNA indicate its negative charge. Reproduced with permission from ref.101 Copyright © 2019 by the authors. Licensee MDPI, Basel, Switzerland. Licensed under CC BY 4.0. GA-Modified Hydrogels Hydrogels, with their superior biocompatibility and controllable swelling/degradation properties, serve as ideal carriers for constructing targeted delivery systems.114 GA-based hydrogels further achieve efficient liver enrichment and controlled drug release by integrating GA’s active targeting capability. Chen et al102 developed a GA-curcumin (Cur) supramolecular progelator for targeted liver cancer therapy. After GA-mediated uptake by hepatoma cells, intracellular disulfide-bond cleavage triggered in situ self-assembly into nanofibrous hydrogels, enabling prolonged retention and sustained drug release. In HepG2 cells, GA-Cur showed a lower IC50 (10.7 μM) than free curcumin (26.5 μM) and the non-targeted control Nap-Cur (29.7 μM), while all three exhibited similar cytotoxicity in normal 3T3 cells, indicating favorable tumor selectivity. This strategy combined active targeting with in situ self-assembly and sustained release, but lacked in vivo validation of targeting efficacy and safety. Lipogels are lipid-polymer hybrid nanoparticles that combine the biocompatibility of liposomes with the high drug-loading capacity and responsive release properties of polymeric gels. Wen et al103 developed a GA-modified lipid–gel hybrid system (GA-SS-LG) for curcumin delivery against liver cancer. A GA-disulfide-cholesterol conjugate provided active liver targeting, while a Ca2+-crosslinked sodium alginate/carboxymethyl chitosan gel formed the internal core. In HepG2 cells, its uptake was 2–3-fold higher than that of free curcumin, and cell viability decreased to 33% at 25 μg/mL. It also outperformed conventional liposomes and unmodified lipogels, with a hemolysis rate below 8%. However, the study was limited to in vitro experiments and lacked validation of pharmacokinetics, biodistribution, and antitumor efficacy in tumor-bearing animals. In summary, GA has been used as a targeting ligand in liposomes, micelles, polymeric nanoparticles, mesoporous silica nanoparticles, metal-organic frameworks, conjugates, and hydrogels to enhance drug uptake and tumor accumulation. Each platform has distinct features: liposomes and polymeric nanoparticles allow flexible control of ligand density and linker structure; micelles are suitable for hydrophobic drugs but may show unstable ligand exposure; mesoporous silica nanoparticles and metal-organic frameworks enable multifunctional delivery but are structurally complex; conjugates and prodrugs depend on linker stability; and hydrogels mainly provide local retention rather than active targeting. GA can also be combined with TAT, RGD, magnetic materials, and ROS or GSH-responsive structures, although this increases formulation complexity. It is noteworthy that the targeting efficiency of GA does not increase linearly with increasing grafting density, but is jointly regulated by ligand density, linker structure, and surface accessibility. Surface accessibility determines the extent of GA exposure on the nanoparticle surface and its availability for receptor binding. Appropriate ligand density enhances GA-receptor recognition, whereas excessive modification may reduce delivery efficiency due to steric hindrance, particle aggregation, or decreased colloidal stability. Studies have shown that increasing the GA grafting ratio from 6% to 20% increased hepatic fluorescence accumulation from 1.8-fold to 2.9-fold compared with the free probe.115 However, excessive ligand modification may impair nanoparticle stability and consequently decrease targeting efficiency.116 Rational linker design can further improve GA exposure and receptor-binding efficiency. GL/GA as Self-Assembling Carrier Materials for Delivery Systems GL and its aglycone GA, leveraging their unique amphiphilic structure and excellent biocompatibility, serve as natural functional molecules for constructing self-assembling nanocarriers.117,118 The core mechanism lies in hydrophobic interactions driven by its amphiphilic molecular structure. In aqueous environments, the hydrophobic moiety (GA aglycone) spontaneously aggregates to avoid the aqueous phase, while the hydrophilic moiety (glucuronic acid or carboxyl group) stabilizes the structure through hydrogen bonding and electrostatic interactions, determining interfacial orientation. By precisely controlling solution conditions (eg, concentration, pH, ionic strength), this delicate balance of forces can guide molecular arrangement into distinct structures: micelles or vesicles form at lower concentrations; under suitable conditions, molecules self-assemble into uniform nanoparticles; and at sufficiently high concentrations, when molecules undergo one-dimensional fiber formation via hydrogen bonds and three-dimensional cross-linking, hydrogels are formed. Thus, the mechanism involves a precisely controllable, multilevel supramolecular assembly process dominated by intermolecular noncovalent interactions. These structures not only effectively encapsulate hydrophobic anticancer drugs, enhancing their solubility and stability, but also confer active targeting capabilities to the carrier. This is achieved through the surface-exposed GL/GA molecules, which can specifically bind to membrane receptors (eg, ASGPR) overexpressed in various cancer cells, including liver cancer.16,119 Therefore, self-assembled drug delivery systems based on GL/GA demonstrate significant application potential in the field of anticancer drug delivery (Table 3 and Figure 7). Table 3Glycyrrhizic Acid/Glyrrhetinic Acid as Self-Assembling Materials for Delivery SystemsDelivery SystemComposition ForceCharacterizationModelTumor SuppressionYear, Ref.BB-GANDsBB, GAIonic interactions;π-π stacking;hydrophobic interactionsSize:~110 nm;Zeta potential: −12.3 mVIn vitro (Huh7 cells)In vivo (H22 tumor-bearing mice)TGI: 64.64%(15 mg/kg)2024120LG-NanosLUT, GAπ-π stacking;hydrogen bondsSize:~250 nm;Zeta potential: −26.8 to −33.7 mVIn vitro (HepG2 cells)In vivo (orthotopic HCC mice)Tumor growth↓;Systemic toxicity↓2025121GGZ NPsGA, GLHydrophobic interactionsSize:~233 nm (TEM);Zeta potential: −50.73 mVIn vitro (Hepa1-6 cells)In vivo (H22 tumor-bearing mice)Tumor growth↓1.8-fold2025122TP/GL-NYPsTP, GLHydrogen bonding;electrostatic interactionSize: 139.25 ± 0.63 nm;Zeta potential: −24.44 ± 1.19 mVIn vitro (H22 cells)In vivo (H22 tumor-bearing BALB/c mice)Tumor volume↓2026123HSG NPsHA, GAHydrophobic interactionsSize: 152.6–260.7 nm;In vitro (HepG2 cells)In vivo (Kunming mice, liver-targeting evaluation)-2017115HGA-PTX NPsHA, GA-NH2Hydrophobic interactionsSize: ~333 nm;Zeta potential: −30.12 mVIn vitro (B16F10/HepG2 cells)In vivo (MDA-MB-231 tumor-bearing mice)TIR (65.08%)↑vs PTX+GA+HA (51.30%).2015124Tf-PIP-NPsGL, PLGAHydrophobic interactions;Hydrogen bondingSize: 112.2 ± 1.27 nm.;Zeta potential: −28.0 ± 1.60 mVIn vitro (HepG2/MDA-MB-231/4T1 cells)In vivo (4T1 tumor-bearing BALB/c mice)Tumor growth↓2021125CPT/Na2GL/TAmicellesNa2GL, TA, CPTHydrogen bonds;hydrophobic interactionSize: 80.15 ± 0.47 nm;Zeta potential: −33.20 ± 1.38 mVIn vitro (HepG-2 cells)In vivo (HepG-2 tumor-bearing BALB/c nude mice)TIR: 93.3%;2021126PZ-FA/Na2GL micellesPZ-FAcocrystal, Na2GLHydrogen bonding;ionic interactionSize: 133.69 ± 1.01 nm;Zeta potential: 62.39 ± 4.48 mVIn vivo (rats, pharmacokinetic study)-2023127GEF/GL-SA nanomicellesGL-SAconjugate, GEFHydrophobic effectsSize: 102 ± 3.6 nmIn vitro (A549 cells)-2025128B-GPSGGPSGHydrophobic effectsSize:102.7±1.09 nm;Zeta potential: −24.5±0.19 mVIn vitro (CBRH-7919 hepatoma cells)In vivo (ICR mice tissue distribution; SD rats pharmacokinetics)-2024129CGA-GLCGA, GLHydrophobic effectsSize: 157.67±2.14 nm;Zeta potential: −35.97±0.60 mVIn vitro (HepG2 cells)In vivo (H22 hepatoma-bearing BALB/c mice)Tumor volume 58.7%↓2025130GA-PEG-SS-CURGA-PEG-SS-CURHydrophobic effectsSize: ~145 nmIn vitro (HepG2 cells; L02 cells)In vivo (Hepatocellular carcinoma xenograft mice)Tumor CUR accumulation↑6-fold;AUC↑2.2-fold; t1/2↑8.3-fold2025131GL@Cur micellar Gel GLHydrophobic interactions; hydrogen bondsSize: 86.33 ± 2.9 nm;Zeta potential: −42.2 mVIn vitro (BV2 cells for biocompatibility)-2023132GK-GL Gel GK, GLHydrophobic interactionsSize: ~200 nmIn vitro (4T1 cells)In vivo (4T1 tumor-bearing BALB/c mice)TGI >90%;No obvious systemic toxicity2023133NCTD Gel GL, Cu2+, NCTDCoordination bonds;hydrogen bondsZeta potential: −35.17 ± 0.47 mVIn vitro (HepG2 cells)In vivo (Hepa1-6 tumor-bearing C57BL/6J mice)TGI↑2023134Cel Gel GL, Cu2+, Cel Coordination bonds;hydrogen bondsSize: 218.0 ± 33.24 nm;Zeta potential: −37.63 ± 1.30 mVIn vitro (4T1 TNBC cells, 3D tumor spheroids, DC/T cell co-culture)In vivo (4T1 tumor-bearing BALB/c mice; bilateral metastatic tumor odel)TIR: 75.41%;+aPD-L1: 91.24% (primary), 88.05% (distant)2025135Lyc@GL-Cu Gel GL, Cu2+, Lyc Coordination bonds;hydrogen bondsZeta potential: −20 ± 0.52 mVIn vitro (SW480 cells)In vivo (CT26 tumor-bearing BALB/c mice)Tumor inhibition↑;Tumor accumulation↑5-fold2025136Note: ↑ and ↓ indicate increases and decreases, respectively, compared with the corresponding control, free drug, or non-targeted formulation groups; > and < indicate greater than and less than, respectively; ± represents standard deviation; ~ indicates an approximate value; vs indicates comparison with.Abbreviations: TGI, tumor growth inhibition; TIR, tumor inhibition rate; AUC, area under the concentration–time curve; t1/2, half-life; TEM, transmission electron microscopy; DC, dendritic cell; aPD-L1, anti-programmed death-ligand 1 antibody. Figure 7Schematic illustration of GL/GA-based self-assembled drug delivery systems constructed through multiple intermolecular interactions. The arrows indicate the assembly process and the representative components involved in different self-assembled systems.An infographic schematic of GL or GA based self assembled drug delivery systems. BB-GA NDs carrier-free is shown with chemical structures and labels, Cu superscript 2 plus, NCTD and Cel. A central oval shows a molecular structure, with five outward arrows to circular callouts labeled, pi minus pi stacking, hydrophobic interaction, electrostatic interaction, coordinate bond and hydrogen bond. The pi minus pi stacking callout shows stacked ring symbols. The hydrophobic interaction callout shows a packed chain arrangement. The electrostatic interaction callout shows two wavy chains with plus signs. The coordinate bond callout shows Cu superscript 2 plus with an oxygen containing group and a Cu superscript 2 plus label. The hydrogen bond callout shows O, OH and O with dotted connections. Additional labeled icons include, minus SS minus, GSH, a porous block, a spiky sphere, a core shell sphere and a small particle with an arrow.Schematic of GL/GA-based self-assembled drug delivery systems via multiple intermolecular interactions. Table 3Glycyrrhizic Acid/Glyrrhetinic Acid as Self-Assembling Materials for Delivery SystemsDelivery SystemComposition ForceCharacterizationModelTumor SuppressionYear, Ref.BB-GANDsBB, GAIonic interactions;π-π stacking;hydrophobic interactionsSize:~110 nm;Zeta potential: −12.3 mVIn vitro (Huh7 cells)In vivo (H22 tumor-bearing mice)TGI: 64.64%(15 mg/kg)2024120LG-NanosLUT, GAπ-π stacking;hydrogen bondsSize:~250 nm;Zeta potential: −26.8 to −33.7 mVIn vitro (HepG2 cells)In vivo (orthotopic HCC mice)Tumor growth↓;Systemic toxicity↓2025121GGZ NPsGA, GLHydrophobic interactionsSize:~233 nm (TEM);Zeta potential: −50.73 mVIn vitro (Hepa1-6 cells)In vivo (H22 tumor-bearing mice)Tumor growth↓1.8-fold2025122TP/GL-NYPsTP, GLHydrogen bonding;electrostatic interactionSize: 139.25 ± 0.63 nm;Zeta potential: −24.44 ± 1.19 mVIn vitro (H22 cells)In vivo (H22 tumor-bearing BALB/c mice)Tumor volume↓2026123HSG NPsHA, GAHydrophobic interactionsSize: 152.6–260.7 nm;In vitro (HepG2 cells)In vivo (Kunming mice, liver-targeting evaluation)-2017115HGA-PTX NPsHA, GA-NH2Hydrophobic interactionsSize: ~333 nm;Zeta potential: −30.12 mVIn vitro (B16F10/HepG2 cells)In vivo (MDA-MB-231 tumor-bearing mice)TIR (65.08%)↑vs PTX+GA+HA (51.30%).2015124Tf-PIP-NPsGL, PLGAHydrophobic interactions;Hydrogen bondingSize: 112.2 ± 1.27 nm.;Zeta potential: −28.0 ± 1.60 mVIn vitro (HepG2/MDA-MB-231/4T1 cells)In vivo (4T1 tumor-bearing BALB/c mice)Tumor growth↓2021125CPT/Na2GL/TAmicellesNa2GL, TA, CPTHydrogen bonds;hydrophobic interactionSize: 80.15 ± 0.47 nm;Zeta potential: −33.20 ± 1.38 mVIn vitro (HepG-2 cells)In vivo (HepG-2 tumor-bearing BALB/c nude mice)TIR: 93.3%;2021126PZ-FA/Na2GL micellesPZ-FAcocrystal, Na2GLHydrogen bonding;ionic interactionSize: 133.69 ± 1.01 nm;Zeta potential: 62.39 ± 4.48 mVIn vivo (rats, pharmacokinetic study)-2023127GEF/GL-SA nanomicellesGL-SAconjugate, GEFHydrophobic effectsSize: 102 ± 3.6 nmIn vitro (A549 cells)-2025128B-GPSGGPSGHydrophobic effectsSize:102.7±1.09 nm;Zeta potential: −24.5±0.19 mVIn vitro (CBRH-7919 hepatoma cells)In vivo (ICR mice tissue distribution; SD rats pharmacokinetics)-2024129CGA-GLCGA, GLHydrophobic effectsSize: 157.67±2.14 nm;Zeta potential: −35.97±0.60 mVIn vitro (HepG2 cells)In vivo (H22 hepatoma-bearing BALB/c mice)Tumor volume 58.7%↓2025130GA-PEG-SS-CURGA-PEG-SS-CURHydrophobic effectsSize: ~145 nmIn vitro (HepG2 cells; L02 cells)In vivo (Hepatocellular carcinoma xenograft mice)Tumor CUR accumulation↑6-fold;AUC↑2.2-fold; t1/2↑8.3-fold2025131GL@Cur micellar Gel GLHydrophobic interactions; hydrogen bondsSize: 86.33 ± 2.9 nm;Zeta potential: −42.2 mVIn vitro (BV2 cells for biocompatibility)-2023132GK-GL Gel GK, GLHydrophobic interactionsSize: ~200 nmIn vitro (4T1 cells)In vivo (4T1 tumor-bearing BALB/c mice)TGI >90%;No obvious systemic toxicity2023133NCTD Gel GL, Cu2+, NCTDCoordination bonds;hydrogen bondsZeta potential: −35.17 ± 0.47 mVIn vitro (HepG2 cells)In vivo (Hepa1-6 tumor-bearing C57BL/6J mice)TGI↑2023134Cel Gel GL, Cu2+, Cel Coordination bonds;hydrogen bondsSize: 218.0 ± 33.24 nm;Zeta potential: −37.63 ± 1.30 mVIn vitro (4T1 TNBC cells, 3D tumor spheroids, DC/T cell co-culture)In vivo (4T1 tumor-bearing BALB/c mice; bilateral metastatic tumor odel)TIR: 75.41%;+aPD-L1: 91.24% (primary), 88.05% (distant)2025135Lyc@GL-Cu Gel GL, Cu2+, Lyc Coordination bonds;hydrogen bondsZeta potential: −20 ± 0.52 mVIn vitro (SW480 cells)In vivo (CT26 tumor-bearing BALB/c mice)Tumor inhibition↑;Tumor accumulation↑5-fold2025136Note: ↑ and ↓ indicate increases and decreases, respectively, compared with the corresponding control, free drug, or non-targeted formulation groups; > and < indicate greater than and less than, respectively; ± represents standard deviation; ~ indicates an approximate value; vs indicates comparison with.Abbreviations: TGI, tumor growth inhibition; TIR, tumor inhibition rate; AUC, area under the concentration–time curve; t1/2, half-life; TEM, transmission electron microscopy; DC, dendritic cell; aPD-L1, anti-programmed death-ligand 1 antibody. Glycyrrhizic Acid/Glyrrhetinic Acid as Self-Assembling Materials for Delivery Systems In vitro (Huh7 cells) In vitro (Huh7 cells) In vivo (H22 tumor-bearing mice) In vivo (H22 tumor-bearing mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (orthotopic HCC mice) In vivo (orthotopic HCC mice) In vitro (Hepa1-6 cells) In vitro (Hepa1-6 cells) In vivo (H22 tumor-bearing mice) In vivo (H22 tumor-bearing mice) In vitro (H22 cells) In vitro (H22 cells) In vivo (H22 tumor-bearing BALB/c mice) In vivo (H22 tumor-bearing BALB/c mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (Kunming mice, liver-targeting evaluation) In vivo (Kunming mice, liver-targeting evaluation) In vitro (B16F10/HepG2 cells) In vitro (B16F10/HepG2 cells) In vivo (MDA-MB-231 tumor-bearing mice) In vivo (MDA-MB-231 tumor-bearing mice) In vitro (HepG2/MDA-MB-231/4T1 cells) In vitro (HepG2/MDA-MB-231/4T1 cells) In vivo (4T1 tumor-bearing BALB/c mice) In vivo (4T1 tumor-bearing BALB/c mice) In vitro (HepG-2 cells) In vitro (HepG-2 cells) In vivo (HepG-2 tumor-bearing BALB/c nude mice) In vivo (HepG-2 tumor-bearing BALB/c nude mice) In vivo (rats, pharmacokinetic study) In vivo (rats, pharmacokinetic study) In vitro (A549 cells) In vitro (A549 cells) In vitro (CBRH-7919 hepatoma cells) In vitro (CBRH-7919 hepatoma cells) In vivo (ICR mice tissue distribution; SD rats pharmacokinetics) In vivo (ICR mice tissue distribution; SD rats pharmacokinetics) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (H22 hepatoma-bearing BALB/c mice) In vivo (H22 hepatoma-bearing BALB/c mice) In vitro (HepG2 cells; L02 cells) In vitro (HepG2 cells; L02 cells) In vivo (Hepatocellular carcinoma xenograft mice) In vivo (Hepatocellular carcinoma xenograft mice) In vitro (BV2 cells for biocompatibility) In vitro (BV2 cells for biocompatibility) In vitro (4T1 cells) In vitro (4T1 cells) In vivo (4T1 tumor-bearing BALB/c mice) In vivo (4T1 tumor-bearing BALB/c mice) In vitro (HepG2 cells) In vitro (HepG2 cells) In vivo (Hepa1-6 tumor-bearing C57BL/6J mice) In vivo (Hepa1-6 tumor-bearing C57BL/6J mice) In vitro (4T1 TNBC cells, 3D tumor spheroids, DC/T cell co-culture) In vitro (4T1 TNBC cells, 3D tumor spheroids, DC/T cell co-culture) In vivo (4T1 tumor-bearing BALB/c mice; bilateral metastatic tumor odel) In vivo (4T1 tumor-bearing BALB/c mice; bilateral metastatic tumor odel) In vitro (SW480 cells) In vitro (SW480 cells) In vivo (CT26 tumor-bearing BALB/c mice) In vivo (CT26 tumor-bearing BALB/c mice) Note: ↑ and ↓ indicate increases and decreases, respectively, compared with the corresponding control, free drug, or non-targeted formulation groups; > and < indicate greater than and less than, respectively; ± represents standard deviation; ~ indicates an approximate value; vs indicates comparison with. Abbreviations: TGI, tumor growth inhibition; TIR, tumor inhibition rate; AUC, area under the concentration–time curve; t1/2, half-life; TEM, transmission electron microscopy; DC, dendritic cell; aPD-L1, anti-programmed death-ligand 1 antibody. Schematic illustration of GL/GA-based self-assembled drug delivery systems constructed through multiple intermolecular interactions. The arrows indicate the assembly process and the representative components involved in different self-assembled systems. GL/GA-Based Self-Assembled Nanoparticles Self-assembled nanoparticles are nanoscale colloidal carriers that spontaneously form through intermolecular noncovalent interactions (eg, hydrophobic interactions, hydrogen bonds, etc).137,138 Leveraging the self-assembly properties of GL and GA, researchers have developed strategies including carrier-free co-assembly, polymer-grafted self-assembly, and multi-component hybrid assembly. Carrier-Free Co-Assembled Nanoparticles These nanoparticles rely not on traditional synthetic carrier materials (eg, lipids, polymers) but instead spontaneously assemble through noncovalent interactions (eg, ion pairing, π-π stacking, hydrophobic interactions) between GL/GA and other active molecules (eg, small-molecule drugs, natural products). This approach not only simplifies the preparation process but also achieves synergistic effects. Xiao et al120 developed self-assembled berberine–glycyrrhetinic acid nanodrugs (BB-GA NDs) at an equimolar ratio using a lipophilic salt-forming strategy. Interionic interactions primarily governed the formation of the BB-GA salt precursor, whereas π–π stacking and hydrophobic interactions acted as secondary forces to promote and stabilize subsequent nanoassembly. The formulation showed approximately 1.8-fold greater antitumor activity against Huh7 cells than free berberine. In H22 tumor-bearing mice, tumor inhibition rates of 57.08% and 64.64% were achieved at doses of 10 and 15 mg/kg, respectively, while the intravenous toxicity of free berberine was markedly reduced. However, the evaluation of in vivo targeting and biodistribution relied mainly on fluorescence imaging, and quantitative pharmacokinetic and free-GA competition studies were lacking. Building on this strategy, researchers further optimized the ratios of active components to improve the stability and synergistic effects of nanoassemblies. Zong et al121 systematically screened different self-assembly ratios of luteolin (LUT) and GA and found that the 1:2 molar ratio produced the strongest overall antitumor performance. π–π stacking was the primary driving force for self-assembly, while hydrogen bonding and electrostatic attraction contributed to structural stabilization. The cumulative dissolution of both LUT and GA exceeded 80% within 15 min, markedly higher than that of the free drugs. In H22 tumor-bearing mice, LG-Nanos showed greater antitumor efficacy than the free drugs and their physical mixtures without evident systemic toxicity. However, pharmacokinetic parameters such as plasma half-life and AUC were not reported. Wang et al122 selected a 2:1 molar ratio of gambogic acid to GL based on reduced toxicity toward normal hepatocytes and constructed GG NPs through hydrophobic interactions. The photosensitizer ZnPc2 was subsequently incorporated to form GGZ NPs for combined chemo–photothermal–photodynamic therapy of liver cancer. In an orthotopic HCC model, GGZ NPs combined with laser irradiation produced 1.8-fold greater tumor-growth inhibition than ZnPc2-mediated phototherapy and alleviated gambogic acid-induced liver injury. This system achieved synergistic enhancement and toxicity reduction through the integration of chemotherapy, photothermal therapy, and photodynamic therapy. However, quantitative pharmacokinetic analysis and long-term repeated-dose safety beyond the 12-day treatment period were not evaluated (Figure 8). Figure 8Diagrammatic illustration of GGZ nanoparticle preparation and combined chemo-phototherapy for tumor treatment. (A) Schematic illustration of the self-assembly process of GGZ nanoparticles from ZnPc 2, GA, and GL. (B) Schematic representation of GGZ nanoparticle-mediated tumor targeting and synergistic chemo-phototherapeutic treatment. Arrows indicate the direction of nanoparticle assembly, delivery, and therapeutic processes. Reproduced with permission from ref.122 Copyright © 2025 The Authors. Published by Elsevier Ltd. Licensed under CC BY-NC-ND 4.0.A schematic illustration of GGZ nanoparticle preparation and tumor treatment. A) Shows the self-assembly process of GGZ nanoparticles from ZnPc 2, GA and GL. B) Depicts GGZ nanoparticle-mediated tumor targeting and treatment. The process involves imaging, synergy and attenuation between tumor and normal cells and targeted uptake. The treatment includes thermoresistance reduction, photothermal therapy (PTT), photodynamic therapy (PDT) and chemotherapy. Arrows indicate the direction of nanoparticle assembly, delivery and therapeutic processes. Labels include orthotopic HCC, PA, i.v., GL receptor, HSP 90, Trx, GSH, ROS and tumor cell death.Two-part diagram of GGZ nanoparticle assembly and tumor treatment process. Diagrammatic illustration of GGZ nanoparticle preparation and combined chemo-phototherapy for tumor treatment. (A) Schematic illustration of the self-assembly process of GGZ nanoparticles from ZnPc 2, GA, and GL. (B) Schematic representation of GGZ nanoparticle-mediated tumor targeting and synergistic chemo-phototherapeutic treatment. Arrows indicate the direction of nanoparticle assembly, delivery, and therapeutic processes. Reproduced with permission from ref.122 Copyright © 2025 The Authors. Published by Elsevier Ltd. Licensed under CC BY-NC-ND 4.0. Multistage assembly strategies have further extended GL-based self-assembled systems from intravenous nanodelivery to oral cancer immunotherapy. Cheng et al123 constructed a nanoparticulate core through hydrogen-bond-driven self-assembly of GL and triptolide (TP), with an optimal binding energy of −4.0 kcal/mol. The core was subsequently encapsulated within yeast cell walls to form an oral microsphere vaccine (NYP) for intestinally targeted delivery. In H22 tumor-bearing mice, NYP reduced tumor volume from 1248.51 to 303.17 mm3, achieved a 90% survival rate in a postoperative recurrence model, and alleviated TP-induced gastrointestinal and hepatic toxicity. However, multistage assembly reduced TP and GL loading from 28.95% and 53.47% to 1.78% and 2.71%, respectively. The lack of a matched GL-free control and an orthotopic liver cancer model left the role of GL and the gut–liver axis delivery mechanism unclear. In summary, these studies demonstrate that carrier-free self-assembled systems can improve drug loading and solubility, enhance tumor accumulation, and achieve synergistic efficacy with reduced toxicity through optimization of component ratios and comprehensive in vitro and in vivo evaluation. However, their in vivo stability, pharmacokinetics, and long-term safety remain insufficiently investigated, requiring more comprehensive in vivo and repeated-dose studies. Polymer-Grafted Self-Assembled Nanoparticles This strategy involves chemically modifying GL/GA to graft them as hydrophobic segments or targeting groups onto hydrophilic polymer backbones (eg, hyaluronic acid, chitosan), synthesizing structurally defined amphiphilic polymers that self-assemble into core-shell nanoparticles with clear structures and enhanced stability. Wang et al115 conjugated GA to the hydroxyl groups of HA through a succinate linker, producing HSG copolymers with different degrees of GA substitution. As the GA substitution degree increased from 6.0% to 20.4%, both the nanoparticle size and the critical aggregation concentration decreased, indicating the formation of a more compact hydrophobic core and improved resistance to dilution. In vivo imaging showed that the hepatic fluorescence accumulation of DiR-loaded HSG-6, HSG-12, and HSG-20 was 1.8, 2.1 and 2.9-fold higher than that of free DiR, respectively, demonstrating a GA substitution-dependent trend. However, liver distribution was evaluated only using a fluorescent probe in healthy mice, without validation in tumor-bearing models or assessment of pharmacokinetics and therapeutic efficacy. In addition, Zhang et al124 used GA-grafted hyaluronic acid conjugates to encapsulate paclitaxel (PTX) and prepared self-assembled PTX-loaded HGA nanoparticles (PTX/HGAs) by dialysis. In MDA-MB-231 tumor-bearing mice, PTX/HGAs achieved a tumor inhibition rate of 65.08%, compared with 51.30% for the physical mixture of PTX, GA, and HA. At the highest tested concentration, the hemolysis rate was only 2.14%, compared with 23.70% for the physical mixture. However, the self-assembly behavior of blank HGA carriers with different substitution degrees was not systematically investigated. Multicomponent Hybrid Nanoparticles This class of systems constructs complex nanoparticles with multi-targeted, synergistic therapeutic capabilities by synergistically assembling or surface-modifying GL/GA with other functional nanocomponents (eg, synthetic polymers, targeting proteins). For instance, Li et al125 constructed a hydrophobic core using GL and PLGA and incorporated Tween 80, hyaluronic acid, and Tf to prepare piperine-loaded Tf-PIP-NPs. Molecular docking suggested that hydrophobic interactions among GL, PLGA, and piperine were the principal driving forces for assembly, while hydrogen bonding contributed to structural stabilization. Tf was adsorbed onto the nanoparticle surface through electrostatic interactions. After 72 h of treatment, Tf-PIP-NPs exhibited a significantly lower IC50 in HepG2 cells than unmodified PIP-NPs and free piperine. In 4T1 breast tumor-bearing mice, Tf-PIP-NPs significantly inhibited tumor growth without evident major-organ damage. However, the assembly mechanism was inferred mainly from molecular docking and requires further experimental validation and evaluation in liver cancer models. Self-Assembled Micelles Based on GL/GA Self-assembled micelles are nanoscale colloidal particles formed by the spontaneous aggregation of amphiphilic molecules in water when their concentration reaches or exceeds the critical micelle concentration (CMC).139,140 Researchers have leveraged the self-assembly properties of GL and GA to construct a series of nanoscale delivery systems through strategies such as physical encapsulation, chemical conjugation, and prodrug assembly. These systems enhance the solubility of poorly soluble drugs, improve their oral bioavailability, and increase targeted delivery efficiency. For instance, ball-milling drugs with GL/GA and excipients creates solid dispersions forming core-shell nanomicelles. Covalently linked amphiphilic conjugates enhance carrier stability and cellular targeting. Furthermore, incorporating stimulus-responsive elements like disulfide bonds enables tumor microenvironment-triggered drug release. These studies provide multiple viable approaches for efficient anticancer drug delivery. Zhang et al126 prepared a solid dispersion by ball-milling camptothecin (CPT), disodium glycyrrhizinate (Na2GL), and tannic acid (TA) at a mass ratio of 1:5:5. Upon dissolution in water, Na2GL self-assembled into micelles and encapsulated CPT, while TA interacted with Na2GL through hydrogen bonding to form a compact outer shell. The resulting micelles had a particle size of approximately 80 nm, increased CPT solubility by 178-fold and AUC by approximately 2.7-fold, and achieved a tumor inhibition rate of 93.3% in a subcutaneous HepG2 xenograft model. However, systemic safety was assessed mainly based on body-weight changes, without clearly reported major-organ histopathology or serum biochemical analyses. Furthermore, Shen et al127 prepared a pazopanib–fumaric acid cocrystal (PZ-FA) and subsequently ball-milled it with disodium glycyrrhizinate at a mass ratio of 1:8 to construct PZ-FA/Na2GL nanocrystalline micelles. In aqueous media, Na2GL self-assembled and incorporated the PZ-FA nanocrystals into its hydrophobic domains. The particle size ranged from 133.69 to 266.24 nm in water and buffers at pH 6.5 and 7.4. The formulation produced a 3.16-fold increase in AUC0-48 relative to raw PZ and maintained an effective plasma concentration for approximately 30 h. However, in vivo experiments used the HepG-2 liver cancer model, while PZ is clinically indicated for renal cell carcinoma and soft tissue sarcoma, with no efficacy validation in relevant tumor models. Additionally, the lack of in vitro cell studies and unclear intermolecular forces driving self-assembly leave the formulation mechanism somewhat ambiguous (Figure 9). Figure 9Molecular structures, TEM morphology, and pharmacokinetic profile of PZ-FA/Na2GL nanocrystalline micelles. The upper panel shows the structures of PZ, FA, and Na2GL (Na2GL; labeled as Na2GA in the original figure), with the pKa values of PZ indicated. (A) Aggregated structures at pH 1.6. (B) Spherical micelles in water. (C) Vesicular micelles at pH 6.5. (D) Spherical and hollow tubular micelles at pH 7.4. The right panel shows the plasma concentration–time profiles of PZ, PM, and PZ-FA/Na2GL after oral administration in rats. Blue symbols indicate component combination and preparation; red arrows and lines indicate representative structures and their measured dimensions. Data are presented as mean ± SD. Reproduced with permission from Ref.127 Copyright © 2023 The Authors. Published by Elsevier B.V. Licensed under CC BY-NC-ND 4.0.Reproduced with permission from ref.132 Copyright© 2023 The Authors. Published by Elsevier B.V. Licensed under CC BY-NC-ND 4.0.The composite image includes molecular structures of PZ, FA and Na subscript 2GL with pKa values of PZ indicated as 2.1 and 6.4. A plus sign connects these structures. Below, four TEM images labeled A, B, C and D show different micelle morphologies. Image A depicts aggregated structures at pH 1.6. Image B shows spherical micelles in water. Image C illustrates vesicular micelles at pH 6.5. Image D presents spherical and hollow tubular micelles at pH 7.4. The right panel features a line graph of PZ plasma concentration over time in micrograms per milliliter, comparing PZ, PZ-FA/Na subscript 2GA and PM. The x-axis is labeled ′Time (h)′ and the y-axis ′PZ Plasma concentration (microg/mL)′. The graph shows PZ-FA/Na subscript 2GA with higher concentrations over time compared to PZ and PM.Composite of molecular structures, TEM morphology and plasma profiles of PZ-FA/Na subscript 2GL micelles. Molecular structures, TEM morphology, and pharmacokinetic profile of PZ-FA/Na2GL nanocrystalline micelles. The upper panel shows the structures of PZ, FA, and Na2GL (Na2GL; labeled as Na2GA in the original figure), with the pKa values of PZ indicated. (A) Aggregated structures at pH 1.6. (B) Spherical micelles in water. (C) Vesicular micelles at pH 6.5. (D) Spherical and hollow tubular micelles at pH 7.4. The right panel shows the plasma concentration–time profiles of PZ, PM, and PZ-FA/Na2GL after oral administration in rats. Blue symbols indicate component combination and preparation; red arrows and lines indicate representative structures and their measured dimensions. Data are presented as mean ± SD. Reproduced with permission from Ref.127 Copyright © 2023 The Authors. Published by Elsevier B.V. Licensed under CC BY-NC-ND 4.0.Reproduced with permission from ref.132 Copyright© 2023 The Authors. Published by Elsevier B.V. Licensed under CC BY-NC-ND 4.0. Based on the natural amphiphilic assembly properties of GL/GA, researchers further enriched the intermolecular interactions of the assembly units by covalently introducing hydrophobic segments or responsive groups. For example, Kumari et al128 covalently conjugated GL with stearylamine (SA) to synthesize an amphiphilic GCA-SA conjugate with a critical micelle concentration of 100 μg/mL. The conjugate further self-assembled into gefitinib-loaded nanomicelles (GNM) for non-small-cell lung cancer treatment. The hydrophobic SA segments formed the micellar core and encapsulated GEF, while the hydrophilic GL moieties formed the outer layer. In A549 cells, GNM showed a significantly lower IC50 than free GEF and enhanced apoptosis while suppressing colony formation and migration. Blank micelles showed no evident cytotoxicity. However, the study was limited to in vitro experiments and lacked PKCα competition or other direct targeting validation, leaving the proposed targeting mechanism insufficiently confirmed. Furthermore, the researchers deeply integrated a “stimulus-responsive” mechanism into the chemical conjugation system and incorporated disulfide bonds (-SS-) into the linker. By ingeniously leveraging the microenvironmental properties of high GSH concentrations within tumor cells, they endowed the micelles with the ability to deliver drugs precisely at target sites. Guan et al129 subsequently used a disulfide-containing GA–polyethylene glycol–glycerol monostearate copolymer (GPSG) to prepare GSH-responsive brucine-loaded micelles (B-GPSG). At the optimized brucine-to-GPSG mass ratio of 6:35, the micelles had a particle size of 102.7 ± 1.09 nm, an encapsulation efficiency of 83.79%, and a drug loading of 12.56%. Their release behavior followed the Higuchi model. The terminal half-life and AUC were approximately 2.6- and 2.5-fold higher than those of free brucine, respectively, and B-GPSG showed greater hepatic accumulation than the non-GA-modified micelles. However, this study did not evaluate the in vivo antitumor efficacy. Guo et al130 further conjugated GA with curcumin (CUR) through a disulfide bond to form the prodrug CGA, which co-assembled with GL into approximately 157.7 nm micelles. Assembly was mainly driven by hydrophobic interactions, while hydrogen bonding and van der Waals forces may have contributed to stabilization. The micelles released 67.5% of CUR within 24 h under 10 mM GSH and achieved a 58.7% reduction in tumor volume with 3.6-fold higher tumor accumulation in H22 tumor-bearing mice. However, the assembly forces and GA-mediated targeting mechanism were not directly validated. Wu et al131 developed GA-PEG-SS-CUR prodrug micelles of approximately 140 nm with a CMC of 43.28 μg/mL. Hydrophobic interactions primarily drove self-assembly. Under 10 mM GSH, 46.7% of CUR was released within 72 h, while the drug half-life and tumor accumulation increased by 8.3 and 6-fold, respectively. However, the study did not directly verify the relative contributions of each force nor evaluate its antitumor efficacy in vivo. GL-Based Self-Assembled Hydrogels GL-based self-assembled hydrogels represent an extension of micellar systems. When the GL concentration exceeds the critical micelle concentration (CMC), its self-assembly can evolve from discrete micelles into a three-dimensional network, resulting in hydrogel formation. This transition not only enhances drug-loading capacity and controlled-release performance but also enables the construction of multifunctional therapeutic platforms through intermolecular interactions such as hydrophobic interactions, hydrogen bonding, and metal coordination.141,142 Micellar hydrogels combine the advantages of micelles and hydrogels by incorporating core-shell micelles into a three-dimensional network. They retain efficient loading of hydrophobic drugs while providing sustained release and reducing burst release.143 Zheng et al132 developed curcumin-loaded micellar hydrogels using GL as a natural amphiphilic carrier through thin-film hydration followed by a heating-cooling process. Self-assembly was primarily driven by hydrophobic interactions, with the hydrophobic aglycone moieties of GL forming the micellar core, while hydrogen bonding provided secondary stabilization. The resulting GL@Cur micelles had a particle size of 86.33 ± 2.9 nm, a zeta potential of −42.2 mV, an encapsulation efficiency of 80.17%, and a drug loading of 10.02%. The hydrogels exhibited shear-thinning, self-healing, and temperature-responsive properties, released approximately 88% of Cur within 8 days, and retained 88.54% of Cur after 72 h at 50 °C. However, the study was limited to in vitro evaluation and lacked validation of in vivo degradation, therapeutic efficacy, and biodistribution. Furthermore, researchers directly co-assembled GL with natural bioactive components to construct carrier-free hydrogel systems. For example, Yang et al133 prepared carrier-free GK-GL nanohydrogels of approximately 200 nm through one-step hydrophobic co-assembly of the bioactive constituents of Genkwa Flos (GK) and GL. The system required no organic solvents and achieved a tumor inhibition rate exceeding 90% following intratumoral administration at 6.25 mg/kg, while markedly reducing lung metastasis without evident toxicity. However, its in vivo degradation, long-term safety, and pharmacokinetics following different administration routes remain to be evaluated. Building upon the carrier-free green co-assembly strategy, researchers further introduced copper ions with multiple bioactivities into the GL self-assembly system. Through synergistic interactions among multiple natural active ingredients, a structurally stable and functionally integrated ternary self-assembled hydrogel was constructed. Within this system, copper ions not only function as structural crosslinkers to enhance stability but also synergize with other drugs through multiple therapeutic mechanisms. These include inducing copper-mediated cell death, catalyzing ROS generation, and modulating the immune microenvironment.144,145 For instance, Pi et al134 co-assembled GL, Cu2+, and norcantharidin (NCTD) at a 2:1:2 molar ratio to form an injectable hydrogel for liver cancer therapy. Assembly was mainly driven by coordination between Cu2⁺ and the carboxyl groups of GL, together with hydrogen bonding between GL and NCTD. Combined with 808 nm laser irradiation, NCTD Gel markedly inhibited Hepa1-6 tumors by promoting ROS generation, GSH depletion, apoptosis, cuproptosis, and anti-inflammatory effects. However, pharmacokinetics, biodegradation, and long-term safety remain unclear (Figures 10 and 11). Figure 10Schematic illustration of NCTD Gel’s self-assembly mechanism and synergistic regulation of the tumor microenvironment via apoptosis, cuproptosis, and anti-inflammatory effects. Gray arrows indicate the direction of material assembly, hydrogel formation, and delivery processes. Blue, green, and Orange arrows represent NCTD-mediated signaling pathways, GL-mediated anti-inflammatory regulation, and Cu2+-related cuproptosis pathways, respectively. The red lightning symbol indicates laser-enhanced Fenton-like reactions. The “+” symbols indicate synergistic interactions among different therapeutic mechanisms. The red dashed box highlights the characteristics of the tumor microenvironment (TME). Numbers ①–③ indicate the corresponding regulatory effects on tumor proliferation, oxidative stress, and inflammation, respectively. Reproduced with permission from ref.134 Copyright© 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. Licensed under CC BY 4.0.The diagram illustrates the self-assembly mechanism of NCTD Gel and its regulation of the tumor microenvironment. It begins with the co-assembly of licorice-derived GA, malachitum-derived Cu2+ and mylabris-derived NCTD through coordination interaction and hydrogen bonding. This forms a natural small molecules carrier-free hydrogel. An 808 nm laser is applied to a mouse, enhancing the Fenton-like reaction. The tumor microenvironment is characterized by tumor proliferation, low pH, hydrogen peroxide, oxygen and severe inflammation. The hydrogel targets the tumor, promoting apoptosis, cuproptosis and anti-inflammatory effects. NCTD, Cu2+ and GA synergistically regulate the tumor microenvironment, leading to cell death. Key pathways include ROS generation, FeS cluster protein loss and DLAT aggregation. The diagram highlights the roles of RAPGEF3, ICAM-1, CD44, IL-1 beta, IL-6, IL-1RN, TNF-alpha and TNFAIP8L2 in these processes.NCTD Gel self-assembly: apoptosis, cuproptosis, anti-inflammatory effects in tumor regulation. Figure 11In vivo antitumor activity of NCTD Gel. (A) Schematic illustration of the experimental design and treatment schedule. (B) Time-dependent changes in body weight. (C) Tumor growth curves during treatment. (D) GSH content in tumor tissues measured by GSH Assay Kit. (E) Photographs of excised tumors after different treatments. (F) In vivo fluorescence imaging of mice after intratumoral injection of NCTD Gel. (G) H&E staining analysis of tumor tissues. Arrows indicate the direction of experimental procedures and treatment processes. Scale bars: 50 μm. Data are presented as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001. Reproduced with permission from ref.134 Copyright© 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. Licensed under CC BY 4.0.A scientific figure illustrates antitumor activity in five groups: Model, GA-Cu, Free NCTD, NCTD Gel and NCTD Gel with laser. Panel A outlines a timeline from tumor implantation to analysis. Panel B shows stable body weights (19-23g) across groups from day 1 to 13. Panel C depicts tumor volume growth; the Model group reaches ~1200 mm superscript 3, while NCTD Gel with laser shows minimal growth. Panel D presents GSH content, with NCTD Gel with laser having the lowest levels, marked by significance indicators. Panel E displays tumor photos, with the NCTD Gel with laser group having the smallest or no tumors. Panel F shows fluorescence imaging post-injection, where NCTD Gel with Cy7 retains signal longer than Free Cy7. Panel G provides H and E stained tumor tissue images, with a 50 microm scale bar.Seven-panel figure showing in vivo antitumor activity of NCTD Gel across treatment groups in mice. Schematic illustration of NCTD Gel’s self-assembly mechanism and synergistic regulation of the tumor microenvironment via apoptosis, cuproptosis, and anti-inflammatory effects. Gray arrows indicate the direction of material assembly, hydrogel formation, and delivery processes. Blue, green, and Orange arrows represent NCTD-mediated signaling pathways, GL-mediated anti-inflammatory regulation, and Cu2+-related cuproptosis pathways, respectively. The red lightning symbol indicates laser-enhanced Fenton-like reactions. The “+” symbols indicate synergistic interactions among different therapeutic mechanisms. The red dashed box highlights the characteristics of the tumor microenvironment (TME). Numbers ①–③ indicate the corresponding regulatory effects on tumor proliferation, oxidative stress, and inflammation, respectively. Reproduced with permission from ref.134 Copyright© 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. Licensed under CC BY 4.0. In vivo antitumor activity of NCTD Gel. (A) Schematic illustration of the experimental design and treatment schedule. (B) Time-dependent changes in body weight. (C) Tumor growth curves during treatment. (D) GSH content in tumor tissues measured by GSH Assay Kit. (E) Photographs of excised tumors after different treatments. (F) In vivo fluorescence imaging of mice after intratumoral injection of NCTD Gel. (G) H&E staining analysis of tumor tissues. Arrows indicate the direction of experimental procedures and treatment processes. Scale bars: 50 μm. Data are presented as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001. Reproduced with permission from ref.134 Copyright© 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. Licensed under CC BY 4.0. Wu et al135 constructed a GL/Cu2⁺/celastrol hydrogel at a 6:3:2 molar ratio for triple-negative breast cancer treatment. Coordination was the dominant driving force, with hydrogen bonding providing additional stabilization. The approximately 218 nm hydrogel inhibited 4T1 tumors by 75.41%; combined with anti-PD-L1, inhibition of primary and distant tumors reached 91.24% and 88.05%, respectively. However, pharmacokinetic and long-term safety data were lacking. Wang et al136 developed a ternary hydrogel composed of GL, Cu2+, and lycorine (Lyc) at a molar ratio of 2:1:2 for colorectal cancer treatment. Assembly was primarily mediated by Cu2+ coordination and hydrogen bonding between GL and Lyc, improving Lyc solubility and prolonging tumor retention. Following intratumoral injection, fluorescence persisted for up to 72 h; at 24 h after intravenous administration, tumor fluorescence was approximately fivefold higher than that of free Cy7. The hydrogel suppressed CT26 tumor growth more effectively than free Lyc by inducing cuproptosis and ROS-mediated PANoptosis, without evident systemic toxicity. However, quantitative pharmacokinetics and the effects of the GL/Lyc ratio on assembly remain to be investigated. Collectively, these studies highlight the potential of natural bioactive component-based self-assembled hydrogels for multimodal cancer therapy. Compared with conventional nanodelivery systems, GL/GA hydrogels provide prolonged local retention, sustained drug release, and structural tunability. Their in situ gelation enables adaptation to irregular lesions and formation of local drug reservoirs, thereby increasing therapeutic exposure while reducing systemic toxicity.GL/GA-metal ion hydrogels are formed through the combined effects of coordination, hydrogen bonding, and hydrophobic interactions rather than a single force. Dynamic coordination between Cu2+ and carboxyl groups is crucial for network stability, whereas hydrogen bonding and hydrophobic interactions promote molecular aggregation and regulate network organization.146 Gelation and performance are also influenced by Cu2+ concentration, pH, and temperature. Cu2+ concentration determines the degree of coordination crosslinking and mechanical strength;134 pH alters carboxyl-group ionization and coordination equilibria, affecting stability and drug release; and temperature influences the dynamic behavior of the hydrogel by regulating molecular mobility and noncovalent interactions.147 Together, these interactions confer injectability, self-healing ability, and tumor-microenvironment responsiveness on GL/GA hydrogels. In summary, GL/GA-based self-assembled delivery systems include carrier-free nanoparticles, polymer-conjugated nanoparticles, micelles, and hydrogels. Through hydrophobic interactions, hydrogen bonding, ion pairing, π–π stacking, and metal coordination, GL/GA can spontaneously assemble with small-molecule drugs, natural bioactive compounds, or functional materials, while simultaneously serving as carriers, targeting ligands, and therapeutic components. These systems are relatively simple to prepare, reduce the use of conventional excipients, improve the solubility, stability, and loading of poorly soluble drugs, and enhance tumor accumulation through targeting, sustained release, and tumor-microenvironment responsiveness. Some platforms further integrate chemotherapy, photothermal/photodynamic therapy, chemodynamic therapy, cuproptosis and immunomodulation to achieve synergistic efficacy and reduced toxicity. Among these platforms, carrier-free nanoparticles offer simple preparation and high component utilization, making them suitable for the co-delivery of multiple active compounds. Polymer-conjugated systems provide greater assembly stability and drug protection, micelles improve the solubilization and delivery of poorly soluble drugs, and hydrogels show particular potential for intratumoral therapy and postoperative local intervention because of their prolonged local retention and sustained release. However, most studies remain limited to in vitro experiments or short-term animal models. Pharmacokinetics, circulatory stability, protein-corona effects, in vivo degradation, long-term safety, and component-ratio optimization require more systematic preclinical evaluation. Conclusions and Perspective This review summarizes the advances in the application of GL and its active metabolite GA in tumor drug delivery systems. GL and GA possess intrinsic antitumor activity, receptor-targeting capability, and self-assembly properties. Their transformation from conventional bioactive compounds into multifunctional nanomedicine components is primarily driven by the integrated exploitation of these multiple attributes to achieve synergistic innovation in delivery-system functions and therapeutic strategies. When GL or GA is used as a therapeutic agent, passive-targeting, active-targeting, and stimuli-responsive formulations exhibit a progressively evolving relationship. Passive targeting relies mainly on the EPR effect, but its efficacy is readily affected by tumor vascular characteristics and interindividual variability148,149 Active targeting improves tissue and cellular recognition through ligand modification or biomimetic membrane coating; however, its effectiveness depends on target expression. Repeated administration of biomimetic membrane-coated formulations may also induce immune or hypersensitivity reactions, whereas denaturation or shedding of membrane proteins may compromise targeting stability and batch-to-batch consistency. Stimuli-responsive formulations exploit tumor-microenvironmental features, such as low pH and elevated GSH levels, to achieve selective drug release, but they also increase the complexity of formulation design, manufacturing, and quality control. These three strategies are not mutually exclusive. In particular, the integration of active targeting with stimuli-responsive release may enable multistage regulation from tumor recognition to intracellular drug release. Notably, when GL or GA is combined with chemotherapeutic agents such as doxorubicin and cisplatin, it may alleviate severe adverse effects, including hepatotoxicity and nephrotoxicity, by counteracting chemotherapy-induced oxidative stress and suppressing the release of inflammatory cytokines, thereby enhancing therapeutic efficacy while reducing toxicity.110 Therefore, GL/GA-based co-delivery strategies may have greater potential for clinical translation. In 2017, the US Food and Drug Administration approved CPX-351 (Vyxeos), a combination liposomal formulation that co-encapsulates daunorubicin and cytarabine at a fixed molar ratio of 1:5, for the treatment of specific types of acute myeloid leukemia.150 LY01616, a combination liposomal formulation of irinotecan hydrochloride and floxuridine developed by Luye Pharma in China, also uses fixed-ratio co-encapsulation and entered a Phase I/II clinical trial in 2021.151 These developments provide valuable translational precedents for GL/GA-based combination delivery systems, although multiple challenges remain. Co-encapsulation does not guarantee pharmacological synergy. Differences among individual components in encapsulation efficiency, release kinetics, tissue distribution, and clearance may cause the formulation ratio to deviate from the actual drug-exposure ratio within tumors. Future studies should therefore integrate combination-index analysis, fixed-ratio formulation design, and quantitative tissue drug measurements to determine the optimal drug ratio, release sequence, and underlying synergistic mechanisms. Comparisons should also be performed with free-drug combinations, separately loaded formulations, and sequential administration regimens.152 Furthermore, engineering challenges remain during scale-up, including control of particle size, drug-loading stability, and batch-to-batch consistency. Consequently, clinical translation depends not only on optimization of drug ratios and synergistic mechanisms but also on the establishment of stable and controllable manufacturing processes and quality-control systems. Currently, clinical GL formulations are used mainly as adjunctive treatments for hepatitis and liver injury, including magnesium isoglycyrrhizinate injection and compound glycyrrhizin tablets. Clinical evidence supporting their use in oncology remains limited.153 An ongoing Phase II window-of-opportunity trial (NCT06378346) is evaluating the effects of GL monotherapy on prostate-specific antigen levels and tumor-tissue gene expression in patients with prostate cancer before surgery. However, its results are not yet available.154 Overall, GL/GA delivery systems require further improvement in terms of synergistic mechanisms, in vivo behavior, manufacturing scale-up, and clinical validation before they can progress from preclinical investigation to clinical application. GA has been widely used as a targeting ligand in drug delivery systems because of its potential liver-targeting capability, favorable biocompatibility, and intrinsic pharmacological activity. Previous studies have shown that GA modification can enhance the uptake of certain formulations by hepatocellular carcinoma cells and increase their accumulation in the liver or tumor tissues. Nevertheless, the molecular identity of the so-called “GA receptor” or GA-binding site has not yet been fully elucidated, and total hepatic accumulation cannot be directly interpreted as active targeting of hepatocellular carcinoma cells. Future investigations should incorporate free-GA competition assays, target-blocking experiments, normal hepatocyte controls, and analyses of hepatic cell subpopulations to distinguish GA-mediated tumor-cell uptake from nonspecific uptake by hepatocytes, macrophages, and other hepatic cell populations. Among the various carrier systems, GA-modified liposomes have been studied relatively extensively.155 Following intravenous administration, liposomes inherently exhibit a certain tendency toward hepatic distribution. In addition, their relatively mature manufacturing technology, broad drug-loading compatibility, and well-established quality-control framework give them considerable translational potential for hepatocellular carcinoma drug delivery. Nevertheless, their performance is influenced by factors such as ligand density, spacer length, conjugation stability, and surface accessibility. Protein-corona formation may also mask GA ligands and reduce targeting-recognition efficiency. For in vivo applications, particular attention should be paid to structural stability following blood dilution, premature drug leakage, and nonspecific clearance by the liver and spleen. During storage, particle aggregation, drug leakage, and stability after lyophilization and reconstitution should also be evaluated. Large-scale manufacturing requires control of ligand-conjugation efficiency, particle size and polydispersity index, the proportion of free drug, and drug-release behavior. The effects of sterilization, process scale-up, and long-term storage on formulation performance and batch-to-batch consistency must likewise be validated. At the biological level, tumor heterogeneity remains an important obstacle. Target expression varies substantially among patients and within different regions of the same tumor. Consequently, a single GA-targeting strategy may fail in tumors with low or absent target expression. Future studies may explore tumor-microenvironment-triggered ligand-exposure designs and validate their targeting efficiency and tissue-penetration capacity in patient-derived organoids, orthotopic tumor models, and humanized models. GL/GA-based self-assembled delivery systems represent a frontier in formulation innovation by integrating carrier structure with therapeutic function. By exploiting their inherent amphiphilicity, coordination ability with metal ions such as Cu2+ or intermolecular interactions with other bioactive molecules such as tannic acid and berberine, diverse dosage forms ranging from nanoparticles and nanomicelles to macroscopic injectable hydrogels can be constructed through relatively simple and environmentally friendly procedures. All three forms have demonstrated clear advantages in improving drug solubility, drug-loading performance, and antitumor efficacy. However, the dominant assembly forces differ among these systems, and their morphology and stability are affected by component ratio, pH, temperature, and ionic concentration. The assembly mechanisms and structure–property relationships should therefore be further clarified. For intravenously administered carrier-free nanoparticles and self-assembled micelles, maintenance of structural integrity in the systemic circulation is critical for clinical translation. After entering the bloodstream, these formulations undergo rapid dilution, changes in ionic strength, and competitive binding with plasma proteins, which may result in dissociation, aggregation, particle-size rearrangement, or premature drug leakage.156 Most existing studies are limited to short-term particle-size measurements in water, phosphate-buffered saline, or low-concentration serum, which are insufficient to reproduce the actual circulatory environment. Future studies should systematically determine the critical aggregation concentration, stability under physiological dilution, protein-corona formation, free-drug fraction, and disassembly kinetics. Dual-labeling strategies or quantitative drug measurements should be used to distinguish the in vivo behavior of intact assemblies from that of free components. Stability after lyophilization and reconstitution, as well as long-term storage stability, should also be evaluated. For polymer-grafted nanoparticles and prodrug micelles, the relationships among grafting density, linker structure, component ratio, polymer degradation behavior, particle size, drug loading, release characteristics, and in vivo exposure should be clearly defined. Compared with nanomedicines intended for systemic administration, GL/GA self-assembled hydrogels may be more suitable for intratumoral injection and sustained local drug delivery. These hydrogels can form in situ and conform to irregular lesions, creating a localized drug reservoir that maintains high local drug concentrations and sustained release while reducing systemic exposure and toxicity to non-target organs. They may also fill the postoperative tumor resection cavity, continuously act on microscopic residual lesions, and provide additional functions such as physical barrier formation, hemostasis, infection reduction, and restriction of tumor-cell dissemination. They therefore have potential for preventing postoperative tumor recurrence.157,158 GL/GA-Cu2+ coordination hydrogels provide a representative example. These systems can continuously release GL or GA together with chemotherapeutic agents, thereby eliminating residual tumor lesions while regulating the local inflammatory microenvironment. Cu2+ can maintain the hydrogel structure through dynamic coordination and simultaneously participate in chemodynamic therapy and cuproptosis. However, excessive metal-ion release may induce reactive oxygen species generation, protein damage, mitochondrial dysfunction, and local inflammation. Metal ions may also accumulate in the liver, kidneys, or injection site. Accordingly, the release kinetics, tissue distribution, long-term clearance, and safety of repeated administration should be comprehensively evaluated. It should be emphasized that the high local drug concentrations generated in postoperative cavities or following intratumoral injection differ markedly from those achieved through intravenous administration.159 Therefore, local tumor-inhibitory and recurrence-preventive effects cannot be directly extrapolated to widely metastatic tumors. The antimetastatic value of these systems remains to be validated in postoperative recurrence and metastasis models. Batch reproducibility and scalable manufacturing constitute another major barrier to the further translation of self-assembled systems. Methods such as thin-film hydration, ultrasonication, solvent evaporation, and heating–cooling procedures are sensitive to the order of component addition, mixing intensity, temperature, and cooling rate. Changes in heat and mass transfer during scale-up may alter nucleation, particle morphology, and component distribution. Therefore, the terms “one-pot synthesis”, “carrier-free”, and “green preparation” do not necessarily imply industrial feasibility.160 Future studies should identify critical material attributes, critical process parameters, and critical quality attributes. Quality specifications should be established for particle size, polydispersity index, component ratio, free-drug content, and release behavior. The effects of different sterilization procedures on the assembled structure and pharmacological activity should also be investigated. Overall, research should move beyond demonstrating that GL/GA systems “can self-assemble” and instead focus on elucidating their assembly mechanisms, in vivo integrity, and structure–property–efficacy relationships, thereby facilitating rational optimization and clinical translation. Taken together, GL and GA have an established pharmacological basis as therapeutic agents, but their independent antitumor potency remains limited. As targeting ligands, they can enhance tissue and cellular uptake, although their application is constrained by the uncertain identity of the relevant targets and insufficient in vivo evidence of active targeting. As self-assembling materials, they provide multiple functional advantages, but challenges related to in vivo stability and engineering-scale manufacturing are more pronounced (Table 4). Some current studies remain limited to cell-level validation. The substantial differences between in vitro and in vivo environments represent a common barrier to the clinical translation of these delivery systems. After entering the bloodstream, nanosystems readily adsorb plasma proteins to form a protein corona and may subsequently undergo immune clearance. High interstitial pressure and dense extracellular matrices within tumors restrict deep tissue penetration, whereas active-targeting strategies are limited by heterogeneous target expression. Consequently, the excellent targeting effects observed in vitro may not be fully reproduced in vivo.161 In addition, long-term or high-dose exposure to GL and GA carries potential toxicity risks. GA can inhibit 11β-hydroxysteroid dehydrogenase type 2 in vivo, resulting in cortisol-mediated overactivation of mineralocorticoid receptors, potassium loss, and elevated blood pressure. This mechanism may constitute a dose-limiting toxicity in patients receiving long-term treatment.162 Current nanomedicine studies have largely focused on short-term therapeutic efficacy, whereas the long-term accumulation, metabolic transformation, and chronic toxicity of GL/GA formulations remain insufficiently investigated. These issues represent major data gaps that must be addressed before clinical translation. Table 4Glycyrrhizic Acid/Glyrrhetinic Acid Delivery Systems and Translational ChallengesFunctionTargeting StrategyRepresentative SystemsFeaturesKey LimitationsDrug Delivery SystemsPassiveTargetingLiposomes, micelles, nanoparticlesEPR effect-dependent tumor accumulationSimple preparation without ligand modificationEPR effect highly heterogeneous in human tumorsLow targeting efficiencyLack of active recognitionLimited efficacyActiveTargetingLigand-modified (Lf, Tf, HA, MDC, etc). liposomes/micelles/nanoparticlesMediate active targeting via ligand modification (Lf, Tf, HA, MDC, etc).Flexible surface modification enables co-delivery of GL/GA with other therapeutics for synergistic effectsHeterogeneous receptor expression across tumorsReceptor expression on normal tissues (off-target risk)Dual-ligand steric hindranceScale-up reproducibility challengesStimuli-ResponsivepH/GSH-responsive systemsTME-triggered drug release (disulfide/thioketal)Enhanced intratumoral retentionMulti-responsive design (active targeting + environment response)In vivo stability of responsive moieties unclearTME heterogeneity affects response efficiencyComplex synthesis and high costTargeting LigandsLigand-ReceptorGL/GA -modified liposomes/micelles/nanoparticles/conjugates/hydrogelsLigand-receptor mediated endocytosisDual-ligand modification (eg, GA+TAT/RGD/PNA)Flexible surface modificationCo-delivery for synergistic effectsGA-R downregulated in some HCC subtypesGA-R expressed on normal hepatocytes (off-target risk)Ligand density-efficacy relationship unclearClinical relevance of GA-R expression poorly understoodSelf-Assembling MaterialsSelf-Assembly Driving ForcesGL/GA conjugates/prodrugs/nanoparticles/micelles/hydrogelsDriven by hydrophobic/π-π/H-bond/ionic interactionsSimple and convenient preparationCarrier-free with high drug loadingBioactive and liver-targetingPoor in vivo stability (dilution/serum-induced disassembly)Assembly kinetics difficult to controlLimited tracking and metabolism data; Batch-to-batch reproducibility Table 4Glycyrrhizic Acid/Glyrrhetinic Acid Delivery Systems and Translational ChallengesFunctionTargeting StrategyRepresentative SystemsFeaturesKey LimitationsDrug Delivery SystemsPassiveTargetingLiposomes, micelles, nanoparticlesEPR effect-dependent tumor accumulationSimple preparation without ligand modificationEPR effect highly heterogeneous in human tumorsLow targeting efficiencyLack of active recognitionLimited efficacyActiveTargetingLigand-modified (Lf, Tf, HA, MDC, etc). liposomes/micelles/nanoparticlesMediate active targeting via ligand modification (Lf, Tf, HA, MDC, etc).Flexible surface modification enables co-delivery of GL/GA with other therapeutics for synergistic effectsHeterogeneous receptor expression across tumorsReceptor expression on normal tissues (off-target risk)Dual-ligand steric hindranceScale-up reproducibility challengesStimuli-ResponsivepH/GSH-responsive systemsTME-triggered drug release (disulfide/thioketal)Enhanced intratumoral retentionMulti-responsive design (active targeting + environment response)In vivo stability of responsive moieties unclearTME heterogeneity affects response efficiencyComplex synthesis and high costTargeting LigandsLigand-ReceptorGL/GA -modified liposomes/micelles/nanoparticles/conjugates/hydrogelsLigand-receptor mediated endocytosisDual-ligand modification (eg, GA+TAT/RGD/PNA)Flexible surface modificationCo-delivery for synergistic effectsGA-R downregulated in some HCC subtypesGA-R expressed on normal hepatocytes (off-target risk)Ligand density-efficacy relationship unclearClinical relevance of GA-R expression poorly understoodSelf-Assembling MaterialsSelf-Assembly Driving ForcesGL/GA conjugates/prodrugs/nanoparticles/micelles/hydrogelsDriven by hydrophobic/π-π/H-bond/ionic interactionsSimple and convenient preparationCarrier-free with high drug loadingBioactive and liver-targetingPoor in vivo stability (dilution/serum-induced disassembly)Assembly kinetics difficult to controlLimited tracking and metabolism data; Batch-to-batch reproducibility Glycyrrhizic Acid/Glyrrhetinic Acid Delivery Systems and Translational Challenges EPR effect-dependent tumor accumulation EPR effect-dependent tumor accumulation Simple preparation without ligand modification Simple preparation without ligand modification EPR effect highly heterogeneous in human tumors EPR effect highly heterogeneous in human tumors Low targeting efficiency Low targeting efficiency Lack of active recognition Lack of active recognition Limited efficacy Limited efficacy Mediate active targeting via ligand modification (Lf, Tf, HA, MDC, etc). Mediate active targeting via ligand modification (Lf, Tf, HA, MDC, etc). Flexible surface modification enables co-delivery of GL/GA with other therapeutics for synergistic effects Flexible surface modification enables co-delivery of GL/GA with other therapeutics for synergistic effects Heterogeneous receptor expression across tumors Heterogeneous receptor expression across tumors Receptor expression on normal tissues (off-target risk) Receptor expression on normal tissues (off-target risk) Dual-ligand steric hindrance Dual-ligand steric hindrance Scale-up reproducibility challenges Scale-up reproducibility challenges TME-triggered drug release (disulfide/thioketal) TME-triggered drug release (disulfide/thioketal) Enhanced intratumoral retention Enhanced intratumoral retention Multi-responsive design (active targeting + environment response) Multi-responsive design (active targeting + environment response) In vivo stability of responsive moieties unclear In vivo stability of responsive moieties unclear TME heterogeneity affects response efficiency TME heterogeneity affects response efficiency Complex synthesis and high cost Complex synthesis and high cost Ligand-receptor mediated endocytosis Ligand-receptor mediated endocytosis Dual-ligand modification (eg, GA+TAT/RGD/PNA) Dual-ligand modification (eg, GA+TAT/RGD/PNA) Flexible surface modification Flexible surface modification Co-delivery for synergistic effects Co-delivery for synergistic effects GA-R downregulated in some HCC subtypes GA-R downregulated in some HCC subtypes GA-R expressed on normal hepatocytes (off-target risk) GA-R expressed on normal hepatocytes (off-target risk) Ligand density-efficacy relationship unclear Ligand density-efficacy relationship unclear Clinical relevance of GA-R expression poorly understood Clinical relevance of GA-R expression poorly understood Driven by hydrophobic/π-π/H-bond/ionic interactions Driven by hydrophobic/π-π/H-bond/ionic interactions Simple and convenient preparation Simple and convenient preparation Carrier-free with high drug loading Carrier-free with high drug loading Bioactive and liver-targeting Bioactive and liver-targeting Poor in vivo stability (dilution/serum-induced disassembly) Poor in vivo stability (dilution/serum-induced disassembly) Assembly kinetics difficult to control Assembly kinetics difficult to control Limited tracking and metabolism data; Batch-to-batch reproducibility Limited tracking and metabolism data; Batch-to-batch reproducibility Future research on GL/GA-based tumor drug delivery should place greater emphasis on mechanisms of action, unmet clinical needs, and practical translational requirements. Delivery strategies should be selected according to the specific role of GL or GA and further validated across multiple experimental models. Pharmacokinetic, pharmacodynamic, long-term toxicity, and repeated-dose assessments should be strengthened to define effective doses, in vivo metabolism, and potential safety risks. During formulation development and translation, formulation design should be optimized, comprehensive quality-control systems should be established, and key issues involving scalable manufacturing, batch-to-batch consistency, and regulatory evaluation should be resolved. With continued improvement of these systems, GL/GA-based delivery platforms may achieve broader applications in precision oncology, combination therapy, and localized tumor intervention.